<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Trifluoperazine versus low‐potency first‐generation antipsychotic drugs for schizophrenia - Tardy, M - 2014 | Cochrane Library</title> <meta content="Trifluoperazine versus low‐potency first‐generation antipsychotic drugs for schizophrenia - Tardy, M - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009396.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Trifluoperazine versus low‐potency first‐generation antipsychotic drugs for schizophrenia - Tardy, M - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009396.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD009396.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Trifluoperazine versus low‐potency first‐generation antipsychotic drugs for schizophrenia" name="citation_title"/> <meta content="Magdolna Tardy" name="citation_author"/> <meta content="Technische Universität München Klinikum rechts der Isar" name="citation_author_institution"/> <meta content="magdolnatardy@yahoo.de" name="citation_author_email"/> <meta content="Markus Dold" name="citation_author"/> <meta content="Technische Universität München Klinikum rechts der Isar" name="citation_author_institution"/> <meta content="Rolf R Engel" name="citation_author"/> <meta content="Ludwig‐Maximilians‐University Munich" name="citation_author_institution"/> <meta content="Stefan Leucht" name="citation_author"/> <meta content="Technische Universität München" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="7" name="citation_issue"/> <meta content="10.1002/14651858.CD009396.pub2" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/07/08" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009396.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009396.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009396.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antipsychotic Agents [adverse effects, *therapeutic use]; Patient Dropouts [statistics &amp; numerical data]; Randomized Controlled Trials as Topic; Schizophrenia [*drug therapy]; Trifluoperazine [adverse effects, *therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009396.pub2&amp;doi=10.1002/14651858.CD009396.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009396.pub2&amp;doi=10.1002/14651858.CD009396.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009396.pub2&amp;doi=10.1002/14651858.CD009396.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009396.pub2&amp;doi=10.1002/14651858.CD009396.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009396.pub2&amp;doi=10.1002/14651858.CD009396.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009396.pub2&amp;doi=10.1002/14651858.CD009396.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009396.pub2&amp;doi=10.1002/14651858.CD009396.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009396.pub2&amp;doi=10.1002/14651858.CD009396.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009396.pub2&amp;doi=10.1002/14651858.CD009396.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009396.pub2&amp;doi=10.1002/14651858.CD009396.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009396.pub2&amp;doi=10.1002/14651858.CD009396.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009396.pub2&amp;doi=10.1002/14651858.CD009396.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009396.pub2&amp;doi=10.1002/14651858.CD009396.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009396.pub2&amp;doi=10.1002/14651858.CD009396.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009396.pub2&amp;doi=10.1002/14651858.CD009396.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009396.pub2&amp;doi=10.1002/14651858.CD009396.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009396.pub2&amp;doi=10.1002/14651858.CD009396.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009396.pub2&amp;doi=10.1002/14651858.CD009396.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009396.pub2&amp;doi=10.1002/14651858.CD009396.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009396.pub2&amp;doi=10.1002/14651858.CD009396.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009396.pub2&amp;doi=10.1002/14651858.CD009396.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009396.pub2&amp;doi=10.1002/14651858.CD009396.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009396.pub2&amp;doi=10.1002/14651858.CD009396.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="fw9sVDQH";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD009396\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD009396\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009396\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009396\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","hr","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD009396.pub2",title:"Trifluoperazine versus low\\u2010potency first\\u2010generation antipsychotic drugs for schizophrenia",firstPublishedDate:"Jul 8, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Schizophrenia Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=fw9sVDQH&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009396.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009396.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD009396.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD009396.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009396.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD009396.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD009396.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD009396.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD009396.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD009396.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1254 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD009396.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009396.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009396.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009396.pub2/full#CD009396-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009396.pub2/full#CD009396-sec-0175"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009396.pub2/full#CD009396-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009396.pub2/full#CD009396-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009396.pub2/full#CD009396-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009396.pub2/full#CD009396-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009396.pub2/full#CD009396-sec-0100"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009396.pub2/full#CD009396-sec-0160"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009396.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009396.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009396.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/table_n/CD009396StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/table_n/CD009396StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009396.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009396.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009396.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009396.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009396.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD009396.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2014 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Trifluoperazine versus low‐potency first‐generation antipsychotic drugs for schizophrenia</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009396.pub2/information#CD009396-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Magdolna Tardy</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009396.pub2/information#CD009396-cr-0003">Markus Dold</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009396.pub2/information#CD009396-cr-0004">Rolf R Engel</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009396.pub2/information#CD009396-cr-0005">Stefan Leucht</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/information/en#CD009396-sec-0188">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 08 July 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD009396.pub2">https://doi.org/10.1002/14651858.CD009396.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD009396-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009396-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009396-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009396-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009396-abs-0002">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD009396-abs-0001" lang="en"> <section id="CD009396-sec-0001"> <h3 class="title" id="CD009396-sec-0001">Background</h3> <p>Antipsychotic drugs are the core treatment for schizophrenia. Treatment guidelines state that there is no difference in efficacy between any other antipsychotic compounds, however, low‐potency antipsychotic drugs are often perceived as less efficacious than high‐potency compounds by clinicians, and they also seem to differ in their side‐effects. </p> </section> <section id="CD009396-sec-0002"> <h3 class="title" id="CD009396-sec-0002">Objectives</h3> <p>To review the effects in response to treatment of trifluoperazine and low‐potency antipsychotics for people with schizophrenia. </p> </section> <section id="CD009396-sec-0003"> <h3 class="title" id="CD009396-sec-0003">Search methods</h3> <p>We searched the Cochrane Schizophrenia Group's Trials Register (November 2010).</p> </section> <section id="CD009396-sec-0004"> <h3 class="title" id="CD009396-sec-0004">Selection criteria</h3> <p>We included all randomised trials comparing trifluoperazine with first‐generation low‐potency antipsychotic drugs for people with schizophrenia or schizophrenia‐like psychosis. </p> </section> <section id="CD009396-sec-0005"> <h3 class="title" id="CD009396-sec-0005">Data collection and analysis</h3> <p>We extracted data independently. For dichotomous data we calculated risk ratios (RR) and their 95% confidence intervals (CI) on an intention‐to‐treat basis based on a random‐effects model. </p> </section> <section id="CD009396-sec-0006"> <h3 class="title" id="CD009396-sec-0006">Main results</h3> <p>The review currently includes seven randomised trials involving 422 participants that compared trifluoperazine with low‐potency antipsychotic drugs. The size of the included studies was between 20 and 157 participants with a study length between four and 52 weeks. Overall, sequence generation, allocation procedures and blinding were poorly reported.<br/> <br/> Trifluoperazine was not significantly different from low‐potency antipsychotic drugs in terms of response to treatment (trifluoperazine 26%, low‐potency drug 27%, 3 RCTs, n = 120, RR 0.96 CI 0.59 to 1.56, <i>moderate quality evidence</i> ). There was also no significant difference in acceptability of treatment with equivocal number of participants leaving the studies early due to any reason (trifluoperazine 20%, low‐potency antipsychotics 16%, 3 RCTs, n = 239, RR 1.25, CI 0.72 to 2.17,<i>low quality evidence</i> ). There was no significant difference in numbers with at least one adverse effect (trifluoperazine 60%, low‐potency antipsychotics 38%, 1 RCT, n = 60, RR 1.60, CI 0.94 to 2.74, <i>moderate quality evidence</i> ). However, at least one movement disorder was significantly more frequent in the trifluoperazine group (trifluoperazine 23%, low‐potency antipsychotics 13%, 2 RCTs, n = 123, RR 2.08 CI 0.78 to 5.55, <i>very low quality evidence</i>) as well as incoordination (trifluoperazine 20%, low‐potency antipsychotics 5%, 1 RCT, n = 60, RR 7.00, CI 1.60 to 30.66) and rigor (trifluoperazine 45%, low‐potency antipsychotics 10%, 1 RCT, n = 60, RR 4.50, CI 1.58 to 12.84). No data were available for other outcomes of interest death, sedation and quality of life. </p> </section> <section id="CD009396-sec-0007"> <h3 class="title" id="CD009396-sec-0007">Authors' conclusions</h3> <p>The results did not show a difference in efficacy between trifluoperazine and low‐potency antipsychotics. Trifluoperazine produced more movement disorders. The number of randomised studies as well as their quality is low, the quality of evidence for outcomes of interest ranged from moderate to very low quality, so more, newer studies would be needed for conclusions about the relative effects of trifluoperazine and low‐potency antipsychotics. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD009396-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009396-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009396-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009396-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009396-abs-0006">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD009396-abs-0005">Hrvatski</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD009396-abs-0004" lang="en"> <h3>Trifluoperazine versus low‐potency first‐generation drugs for schizophrenia</h3> <p>Antipsychotic drugs are the main treatment for schizophrenia, they help people cope with symptoms such as hearing voices, seeing things and having strange beliefs. Guidelines state that there is no difference in effectiveness between antipsychotics, but low‐potency antipsychotic drugs are often seen as less effective than high‐potency drugs, and they also seem to differ in side‐effects. The classification into high‐potency and low‐potency medication means that low‐potency antipsychotic drugs need higher doses for treating the symptoms of schizophrenia. Side‐effects that are common to most high‐potency antipsychotic drugs include the movement disorders such as uncontrollable movements of the face, arms, or legs; tremors; problems with balance or walking; restlessness; seizures; joint pain whereas low‐potency drugs are more likely to cause sedation, fever and loss of muscle strength. Research has not evaluated and compared high‐potency drugs with low‐potency antipsychotic drugs. The aim of the review was therefore to compare trifluoperazine (a high‐potency antipsychotic) with low‐potency antipsychotics for people with schizophrenia. Examples of low‐potency drugs are chlorpromazine, chlorprothixene, thioridazine and levomepromazine. The review is based on a search carried out in 2010 and included seven studies with a total of 422 people. It compared trifluoperazine with low‐potency antipsychotic drugs. Overall, information was poorly reported and the quality of the studies was low; authors rated the quality of evidence for the main outcomes of interested as being either moderate, low or very low quality. Results do not show a superiority of trifluoperazine compared with low‐potency antipsychotics. However, at least one movement disorder (muscle stiffness) was significantly more with trifluoperazine. For people with schizophrenia it is important to know that trifluoperazine and low‐potency antipsychotics are approximately equal for dealing with symptoms such as hearing voices or seeing things. They differ slightly in their side‐effects, with trifluoperazine leading to at least one movement disorder (muscle stiffness). However, no clear superiority of trifluoperazine versus low‐potency antipsychotics was found. Due to the limited number of studies, participants and low quality of information, these results have to be interpreted with caution.  </p> <p>This plain language summary has been written by a consumer Benjamin Gray, Service User and Service User Expert, Rethink Mental Illness. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD009396-sec-0175" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD009396-sec-0175"></div> <h3 class="title" id="CD009396-sec-0176">Implications for practice</h3> <section id="CD009396-sec-0176"> <section id="CD009396-sec-0177"> <h5 class="title">1. For clinicians</h5> <p>Clinicians should know that we did not find differences in the efficacy between trifluoperazine and low‐potency antipsychotics, but that low‐potency antipsychotics appear to produce fewer movement disorders (measured as 'at least one movement disorder' and rigor). Due to the limited number of studies and participants, and due to low quality, the results have to be interpreted with caution. </p> </section> <section id="CD009396-sec-0178"> <h5 class="title">2. For people with schizophrenia</h5> <p>For people with schizophrenia it is important to know that there is low quality evidence that trifluoperazine and low‐potency antipsychotics are approximately equal in their effects on treatment response, and that there is evidence of lower quality that they clearly differ in side‐effects (such as movement disorders).<br/> <br/> They might tell their doctors that they want to be involved in the choice of the antipsychotic that is best for them. </p> </section> <section id="CD009396-sec-0179"> <h5 class="title">3. For managers/policy makers</h5> <p>There were no data on rehospitalisation, economic outcomes, healthy days or quality of life, which can be considered very important outcomes for decision makers. Thus, it is not possible to make any recommendations apart from the fact that all of the examined drugs in this review have lost their patent protection and are therefore rather inexpensive. </p> </section> </section> <h3 class="title" id="CD009396-sec-0180">Implications for research</h3> <section id="CD009396-sec-0180"> <section id="CD009396-sec-0181"> <h5 class="title">1. General</h5> <p>The outcome reporting about the effects of trifluoperazine versus low‐potency antipsychotics on clinical response was insufficient. Strict adherence to the CONSORT statement (<a href="./references#CD009396-bbs2-0069" title="SchulzKF , AltmanDG , MoherD . CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ2010;340(c332):698‐702. ">Moher 2010</a>) would make such studies much more informative. </p> </section> <section id="CD009396-sec-0182"> <h5 class="title">2. Specific</h5> <section id="CD009396-sec-0183"> <h6 class="title">2.1 Reviews</h6> <p>Studies we have had to exclude because they were not directly relevant, however, do still show how this compound has been evaluated in many other ways. Some of these remain clinically relevant and may merit further systematic reviews (<a href="#CD009396-tbl-0003">Table 2</a>). </p> <div class="table" id="CD009396-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Other reviews suggested by excluded studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Suggested title</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Excluded study tag</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Alternate use of different antipsychotics for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009396-bbs2-0034" title="WilsonIC , McKayJ , SandiferMG . A double‐blind trial to investigate the effects of thorazine (largactil, chlorpromazine), compazine (stemetil, prochlorperazine) and stelazine (trifluoperazine) in paranoid schizophrenia. Journal of Mental Science1961;107:90‐9. ">Wilson 1961</a> (trifluoperazine and chlorpromazine) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Combined multi‐drug therapy for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009396-bbs2-0009" title="CaseyJF , HollisterLE , KlettCJ , LaskyJJ , CaffeyEM . Combined drug therapy of chronic schizophrenics. Controlled evaluation of placebo, dextro‐amphetamine, imipramine, isocarboxazid and trifluoperazine added to maintenance doses of chlorpromazine. American Journal of Psychiatry1961;117:997‐1003. ">Casey 1961</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trifluoperazine and chlorpromazine combination for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009396-bbs2-0013" title="DeWolfeAS , BarrellRP , LondonL , SpanerFE . Prolixin enanthate and thorazine‐stelazine regimens in the treatment of schizophrenic patients. An experimental evaluation. Psychosomatics1971;12(3):186‐90. ">DeWolfe 1971</a>, <a href="./references#CD009396-bbs2-0026" title="SmithJA , ChristianD , RutherfordA , MansfieldE . A comparison of triflupromazine (vesprin), chlorpromazine and PLACEBO in 85 chronic patients. American Journal of Psychiatry1958;115:253‐4. ">Smith 1958</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trifluoperazine doses for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009396-bbs2-0011" title="CraneGE . High doses of trifluperazine and tardive dyskinesia. Archives of Neurology1970;22(2):176‐80. ">Crane 1970</a>, <a href="./references#CD009396-bbs2-0024" title="PrienRF , LevineJ , ColeJO . High dose trifluoperazine therapy in chronic schizophrenia. American Journal of Psychiatry1969;126(3):305‐13. ">Prien 1969</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trifluoperazine versus mid‐potency antipsychotics for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009396-bbs2-0016" title="GardosG , FinnertyRJ , ColeJO . Thiothixene and trifluoperazine in a step system. Psychosomatics1970;11(1):36‐40. ">Gardos 1970</a> (thiothixene), <a href="./references#CD009396-bbs2-0018" title="HamiltonM , HordernA , WaldropFN , LofftJ . A controlled trial on the value of prochlorperazine, trifluoperazine and intensive group treatment. British Journal of Psychiatry1963;109:510‐22. ">Hamilton 1963</a> (prochlorperazine) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trifluoperazine versus other high‐potency antipsychotics and anxiolytics for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009396-bbs2-0021" title="MarjerrisonG , HrychukW , VarsanyiEI . A comparison of two butyrophenones with trifluoperazine. Canadian Psychiatric Association Journal1966;11(1):26‐30. ">Marjerrison 1966</a> (triperidol, haloanisone), <a href="./references#CD009396-bbs2-0023" title="PrienRF , LevineJ , ColeJO . High dose therapy in chronic schizophrenia ‐ trifuoperazine. Proceedings of the 121st Annual Meeting of the American Psychiatric Association; 1968 May 13‐17; Boston, Massachusetts, USA. 1968. ">Prien 1968</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trifluoperazine versus other phenothiazine (unknown) antipsychotics for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009396-bbs2-0025" title="RudyL , RinaldiE , HimwichH , TuteurW , GlotzerJ . Trifluoperazine in the treatment of psychotic patients. American Journal of Psychiatry1958;115:364‐5. ">Rudy 1958</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trifluoperazine versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009396-bbs2-0019" title="HershonHI , KennedyPF , McGuireRJ . Persistence of extra‐pyramidal disorders and psychiatric relapse after withdrawal of long‐term phenothiazine therapy. British Journal of Psychiatry1972;120(554):41‐50. ">Hershon 1972</a>, <a href="./references#CD009396-bbs2-0022" title="PlatzAR , KlettCJ , CaffeyEM . Selective drug action related to chronic schizophrenic subtype (A comparative study of carphenazine, chlorpromazine, and trifluoperazine). Diseases of the Nervous System1967;28(9):601‐5. ">Platz 1967</a>, <a href="./references#CD009396-bbs2-0024" title="PrienRF , LevineJ , ColeJO . High dose trifluoperazine therapy in chronic schizophrenia. American Journal of Psychiatry1969;126(3):305‐13. ">Prien 1969</a>, <a href="./references#CD009396-bbs2-0033" title='WestonFK , LoftusAP . A terminal double‐blind trial of tri‐fluoperazine ("stelazine") in chronic schizophrenia. Medical Journal of Australia1961;48(1):776‐80. '>Weston 1961</a> </p> </td> </tr> </tbody> </table> </div> </section> <section id="CD009396-sec-0184"> <h6 class="title">2.2 Trials</h6> <p>Even the number of studies providing data on the primary outcome response to treatment, let alone on most adverse events was very low, as well as the overall quality of the included studies. Thus it would be warranted to have newer and longer studies studying the difference between trifluoperazine and low‐potency antipsychotic drugs, as first‐generation antipsychotic drugs are still frequently prescribed, not only in poorer countries but also in countries for example, Germany. We suggest a design of a future study in <a href="#CD009396-tbl-0004">Table 3</a>. </p> <div class="table" id="CD009396-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Design of a future study</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Methods</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: randomised ‐ clearly described generation of sequence and concealment of allocation.<br/> Blinding: double ‐ described and tested.<br/> Duration: long term. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>People with schizophrenia or schizophrenia‐like disorder.<br/> N = 500.<br/> Age: any.<br/> Sex: both.<br/> History: any. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Trifluoperazine (oral).</p> <p>2. Any low‐potency antipsychotic (oral).</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Response (primary outcome)</p> <p>Rehospitalisation</p> <p>Mental state (BPRS)</p> <p>Global state (CGI)</p> <p>Leaving the study early (including specific causes)</p> <p>Death (natural and unnatural causes)</p> <p>Side‐effects</p> <p>Quality of life</p> <p>Satisfaction with care</p> <p>Employment</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>BPRS ‐ Brief Psychiatric Rating Scale<br/> CGI ‐ Clinical Global Impression </p> </div> </div> </section> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD009396-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD009396-sec-0022"></div> <div class="table" id="CD009396-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Trifluoperazine versus low‐potency antipsychotic drugs for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Trifluoperazine versus low‐potency antipsychotic drugs for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with schizophrenia<br/> <b>Settings:</b> Inpatients and outpatients<br/> <b>Intervention:</b> Trifluoperazine versus low‐potency antipsychotic drugs </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Trifluoperazine versus low‐potency antipsychotic drugs</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Response to treatment ‐ medium term</b> <br/> Follow‐up: 4‐6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.96</b> <br/> (0.59 to 1.56) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>120<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>364 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>349 per 1000</b> <br/> (215 to 567) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>350 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>336 per 1000</b> <br/> (206 to 546) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Leaving the study early: 1. Acceptability of treatment ‐ leaving early due to any reason</b> <br/> Follow‐up: 1‐4 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.25</b> <br/> (0.72 to 2.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>239<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>160 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> <br/> (115 to 348) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>182 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>228 per 1000</b> <br/> (131 to 395) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse events: 1. General ‐ at least one adverse effect</b> <br/> Follow‐up: mean 4 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.6</b> <br/> (0.94 to 2.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>60<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>375 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>600 per 1000</b> <br/> (352 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>375 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>600 per 1000</b> <br/> (352 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse events: 2.a. Specific ‐ movement disorders ‐ at least one movement disorder</b> <br/> Follow‐up: 6‐26 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 2.08</b> <br/> (0.78 to 5.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>123<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>89 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>186 per 1000</b> <br/> (70 to 496) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>104 per 1000</b> <br/> (39 to 278) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0<sup>4</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sedation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0<sup>5</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0<sup>5</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect. <br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk of bias: rated 'serious' ‐ most information is from studies at unclear risk of bias, missing or unclear results for incomplete outcome data and selective reporting<br/> <sup>2</sup> Imprecision: rated 'serious' ‐ the total number of events is less than 300 and the estimate of effect includes appreciable benefit/harm.<br/> <sup>3</sup> Imprecision: rated 'serious' ‐ the total number of events is less than 300 and the CI is quite wide<br/> <sup>4</sup> There were no data for this very important outcome<br/> <sup>5</sup> There were no data for this outcome </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD009396-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD009396-sec-0023"></div> <section id="CD009396-sec-0024"> <h3 class="title" id="CD009396-sec-0024">Description of the condition</h3> <p>Schizophrenia is often a chronic and disabling psychiatric disorder. It afflicts approximately one per cent of the population world‐wide with little gender differences. Its typical manifestations are 'positive' symptoms such as fixed, false beliefs (delusions) and perceptions without cause (hallucinations), 'negative' symptoms such as apathy and lack of drive, disorganisation of behaviour and thought, and catatonic symptoms such as mannerisms and bizarre posturing (<a href="./references#CD009396-bbs2-0041" title="CarpenterWT , BuchananRW . Schizophrenia. New England Journal of Medicine1994;330:681‐90. ">Carpenter 1994</a>). The degree of suffering and disability is considerable with 80% to 90% of people with schizophrenia not working (<a href="./references#CD009396-bbs2-0068" title="MarwahaS , JohnsonS . Schizophrenia and employment ? a review. Social Psychiatry and Psychiatric Epidemiology2004;39:337‐49. ">Marvaha 2004</a>) and up to 10% dying by suicide (<a href="./references#CD009396-bbs2-0079" title="TsuangMT . Suicide in schizophrenics, manics, depressives, and surgical controls: a comparison with general population suicide mortality. Archives of General Psychiatry1978;35:153‐5. ">Tsuang 1978</a>). </p> </section> <section id="CD009396-sec-0025"> <h3 class="title" id="CD009396-sec-0025">Description of the intervention</h3> <p>Antipsychotic drugs are the mainstay of treatment for schizophrenia. They can be classified according to their biochemical structure (e.g. butyrophenones, phenothiazines, thioxanthenes etc), their risk of producing movement disorders ('atypical' versus 'typical' antipsychotics) and the doses necessary for an antipsychotic effect (high‐potency versus low‐potency antipsychotics). The classification into high‐potency and low‐potency medication means that for low‐potency antipsychotic drugs higher doses are necessary to obtain the same dopamine receptor occupancy and efficacy (<a href="./references#CD009396-bbs2-0073" title="SeemanP , LeeT . Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science1975;188:1217‐9. ">Seeman 1975</a>) than for high‐potency antipsychotic drugs. In this context, trifluoperazine belongs to the high‐potency antipsychotic drug group. It is a conventional antipsychotic drug with a primary indication for schizophrenia. </p> <p>Typical examples for low‐potency drugs are chlorpromazine, chlorprothixene, thioridazine or levomepromazine. It is an old psychiatric dogma that can be found in textbooks and guidelines that ‐ with the exception of clozapine ‐ there is no difference in efficacy between any antipsychotic compounds (<a href="./references#CD009396-bbs2-0051" title="GaebelW , FalkaiP , WeinmannS . Behandlungsleitlinie Schizophrenie. Darmstadt: Steinkopff, 2006. ">Gaebel 2006</a>; <a href="./references#CD009396-bbs2-0060" title="LehmanAF , LiebermanJ.A , DixonLB . Practice guideline for the treatment of patients with schizophrenia, second edition. American Journal of Psychiatry2004;161:1‐56. ">Lehman 2004</a>). Nevertheless, low‐potency antipsychotic drugs are often clinically perceived as less efficacious than high‐potency compounds, and high‐ and low‐potency antipsychotics also seem to differ in their side‐effects. For example, low‐potency drugs are more likely to cause sedation or hypotonia, whereas high‐potency drugs are more prone to produce extrapyramidal side‐effects. This is one of a series of similar reviews on the question whether there are differences between high‐potency and low‐potency antipsychotics (<a href="#CD009396-tbl-0002">Table 1</a>). </p> <div class="table" id="CD009396-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Series of similar reviews</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reference</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol versus low‐potency antipsychotic drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009396-bbs2-0076" title="TardyM , LeuchtS , PotapovA , KisslingW , EngelR , HuhnM , et al. Haloperidol versus low‐potency first‐generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews2011, Issue 8. [DOI: 10.1002/14651858.CD009268] ">Tardy 2011b</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flupenthixol versus low‐potency antipsychotic drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009396-bbs2-0074" title="TardyM , LeuchtS , PotapovA , EngelR , DoldM , KisslingW . Flupenthixol versus low‐potency first generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews2011, Issue 8. [DOI: 10.1002/14651858.CD009227] ">Tardy 2011</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fluphenazine versus low‐potency antipsychotic drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009396-bbs2-0075" title="TardyM , LeuchtS , PotapovA , EngelR , HuhnM , KisslingW . Fluphenazine versus low‐potency first generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews2011, Issue 8. [DOI: 10.1002/14651858.CD009230] ">Tardy 2011a</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Perphenazine versus low‐potency antipsychotic drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009396-bbs2-0077" title="TardyM , LeuchtS , PotapovA , EngelR , HuhnM , KisslingW . Perphenazine versus low‐potency first generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews2011, Issue 10. [DOI: 10.1002/14651858.CD009369] ">Tardy 2011c</a> </p> </td> </tr> </tbody> </table> </div> </section> <section id="CD009396-sec-0026"> <h3 class="title" id="CD009396-sec-0026">How the intervention might work</h3> <p>Schizophrenia is considered to be a chronic disorder caused by hyper‐dopaminergic states in the limbic system (<a href="./references#CD009396-bbs2-0037" title="BergerM . Psychische Erkrankungen. Klinik und Therapie. 2nd Edition. München: Urban &amp; Fischer, 2003. ">Berger 2003</a>). All antipsychotic drugs are believed to exert their effects by blocking, to a greater or lesser extent, D2‐receptors in the brain.<br/> <br/> Trifluoperazine is a phenothiazine that is considered a high‐potency antipsychotic along with drugs such as haloperidol and fluphenazine. In higher doses it is used in the treatment of psychiatric illnesses. In lower doses it has also been used in the management of nausea and vomiting. It works by blocking dopamine D1 and D2 receptors in the mesocortical and mesolimbic pathways, thereby minimising symptoms of schizophrenia, such as hallucinations and delusions. Possible side‐effects, common to high‐potency antipsychotics, include uncontrollable movements of face, arms, or legs, tremor, problems with balance or walking, restlessness, seizures, joint pain or unusual thoughts or behaviour. </p> <p>Low‐potency medications have a lower affinity for dopamine receptors so that a higher dose is required to effectively treat symptoms of schizophrenia. In addition, they block other than dopamine receptors, such as cholinergic or histaminergic receptors. This also explains the occurrence of their side‐effects, mostly sedation, hypotonia or fever, which occur less frequently with high‐potency drugs. The distinction between high‐ and low‐potency drugs is not entirely clear, but attempts have been made to express this in terms of dose equivalence. The most frequently applied concept is based on chlorpromazine equivalents. <a href="./references#CD009396-bbs2-0042" title="DavisJM . Overview: maintenance therapy in psychiatry: I. Schizophrenia. American Journal of Psychiatry1975;132(12):1237‐45. ">Davis 1974</a> and <a href="./references#CD009396-bbs2-0053" title="HaaseHJ . Dosierung der Neuroleptika. Ein Leitfaden für Klinik und Praxis unter besonderer Berücksichtigung psychotisch Kranker. Erlangen: Perimed Fachbuch‐Verlagsgesellschaft, 1983. ">Haase 1983</a>, among others, provide data about comparable doses of various antipsychotic drugs to achieve an effect similar to 100 mg chlorpromazine. </p> </section> <section id="CD009396-sec-0027"> <h3 class="title" id="CD009396-sec-0027">Why it is important to do this review</h3> <p>Cochrane systematic reviews on the effects of specific conventional antipsychotic drugs have compared the effects of one antipsychotic drug versus any other antipsychotic drug (e.g. <i>Pimozide versus any other antipsychotic drug</i> (<a href="./references#CD009396-bbs2-0071" title="RathboneJ , McMonagleT . Pimozide for schizophrenia or related psychoses. Cochrane Database of Systematic Reviews2007, Issue 3. [DOI: 10.1002/14651858.CD001949.pub2] ">Rathbone 2007</a>). Systematic reviews have not evaluated the comparative effects of high‐potency and low‐potency antipsychotic drugs. As a result, many guidelines, such as the German national schizophrenia guidelines (<a href="./references#CD009396-bbs2-0051" title="GaebelW , FalkaiP , WeinmannS . Behandlungsleitlinie Schizophrenie. Darmstadt: Steinkopff, 2006. ">Gaebel 2006</a>), or that of the World Federations of Societies of Biological Psychiatry (<a href="./references#CD009396-bbs2-0049" title="FalkaiP , WobrockT , LiebermanJ . World Federation of Societies of Biological Psychiatry (WFSBP) ‐ Guidelines for biological treatment of schizophrenia, part 1: Acute treatment of schizophrenia. World Journal of Biololgical Psychiatry2005;6:132‐91. ">Falkai 2005</a>), state that “all conventional antipsychotics if adequately dosed have comparable efficacy.” These guidelines contrast with a clinical impression that low‐potency conventional antipsychotic drugs are less efficacious than high‐potency conventional antipsychotic drugs and that their side‐effects differ considerably. </p> <p>Conventional antipsychotic drugs are still the mainstay of treatment in countries that can not afford newer, expensive "atypical" or "second‐generation" antipsychotic drugs. But even in some industrialised countries such as Germany, conventional antipsychotic medications still account for 50% of the market‐share (<a href="./references#CD009396-bbs2-0066" title="LohseMJ , LorenzenA , Müller‐OerlinghausenB . Psychotropic drugs [Psychopharmaka]. Arzneimittel Verordnungs Report2005:820‐64. ">Lohse 2005</a>). Recent studies have also called into question the superiority of the more expensive second‐generation antipsychotics (<a href="./references#CD009396-bbs2-0064" title="LeuchtS , CorvesC , ArbterD , EngelR , LiC , DavisJM . A meta‐analysis comparing second‐generation and first‐generation antipsychotics for schizophrenia. Lancet2009;373:31‐41. ">Leucht 2009</a>; <a href="./references#CD009396-bbs2-0065" title="LiebermanJA , StroupTS , McEvoyJP . Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine2005;353:1209‐23. ">Lieberman 2005</a>; <a href="./references#CD009396-bbs2-0057" title="JonesPB , BarnesTRE , DaviesL . Randomized controlled trial of the effect on quality of life of second‐ vs first‐generation antipsychotic drugs in schizophrenia ‐ cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Archives of General Psychiatry2006;63:1079‐86. ">Jones 2006</a>). Therefore, research on conventional antipsychotic agents is essential. The results of this review could aid our understanding of the comparative efficacy and safety of conventional antipsychotic drugs. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD009396-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD009396-sec-0028"></div> <p>To evaluate the effects of the high‐potency antipsychotic drug trifluoperazine versus low‐potency antipsychotic drugs. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD009396-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD009396-sec-0029"></div> <section id="CD009396-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD009396-sec-0031"> <h4 class="title">Types of studies</h4> <p>We included all randomised controlled (parallel group or cross‐over) trials irrespective of duration. We included trials that were described as randomised or where randomisation was implied. We excluded quasi‐randomised trials, such as those that used alternation, an open list of random numbers, or any other method of recruitment where allocation to interventions was predictable. </p> </section> <section id="CD009396-sec-0032"> <h4 class="title">Types of participants</h4> <p>People with schizophrenia and schizophrenia‐like psychoses (schizophreniform and schizoaffective disorders). There is no clear evidence that the schizophrenia‐like psychoses are caused by fundamentally different disease processes or require different treatment approaches (<a href="./references#CD009396-bbs2-0041" title="CarpenterWT , BuchananRW . Schizophrenia. New England Journal of Medicine1994;330:681‐90. ">Carpenter 1994</a>). We included studies irrespective of the diagnostic criteria used. Diagnostic criteria, such as ICD 10 (International Classification of Diseases, tenth revision) or DSM‐IV (Diagnostic and Statistical Manual of Mental disorders, version IV), are not meticulously used in clinical practice and restricting inclusion to trials that used operationally defined diagnostic criteria would have reduced generalisation and representativeness. </p> <p>We were interested in making sure that information is as relevant to the current care of people with schizophrenia as possible so proposed to clearly highlight the current clinical state (acute, early post‐acute, partial remission, remission) as well as the stage (prodromal, first episode, early illness, persistent) and as to whether the studies primarily focused on people with particular problems (for example, negative symptoms, treatment‐resistant illnesses). </p> </section> <section id="CD009396-sec-0033"> <h4 class="title">Types of interventions</h4> <section id="CD009396-sec-0034"> <h5 class="title">1. Intervention: Trifluoperazine</h5> <p>Any dose of oral mode of administration (no depots, no short‐acting parenteral forms of administration). </p> </section> <section id="CD009396-sec-0035"> <h5 class="title">2. Comparators: Low‐potency antipsychotic drugs</h5> <p>Low‐potency conventional antipsychotic drugs in any oral form of administration and used at any dose. We used the dose equivalence tables by <a href="./references#CD009396-bbs2-0042" title="DavisJM . Overview: maintenance therapy in psychiatry: I. Schizophrenia. American Journal of Psychiatry1975;132(12):1237‐45. ">Davis 1974</a> and/or <a href="./references#CD009396-bbs2-0053" title="HaaseHJ . Dosierung der Neuroleptika. Ein Leitfaden für Klinik und Praxis unter besonderer Berücksichtigung psychotisch Kranker. Erlangen: Perimed Fachbuch‐Verlagsgesellschaft, 1983. ">Haase 1983</a> to define drugs as low‐potency if the chlorpromazine equivalence was roughly equal or higher than chlorpromazine. The chlorpromazine equivalences of sulpiride are often estimated to be approximately 100. However, its properties are similar to those of amisulpride, which is an atypical antipsychotic and not within the scope of this review. Moreover, sulpiride does not cause a lot of sedation, which is another important characteristic of low‐potency antipsychotics. Therefore, we decided that we would not consider sulpiride in this review. </p> </section> </section> <section id="CD009396-sec-0036"> <h4 class="title">Types of outcome measures</h4> <section id="CD009396-sec-0037"> <h5 class="title">Primary outcomes</h5> <section id="CD009396-sec-0038"> <h6 class="title">1. Clinical response</h6> <p>Response to treatment as defined by the original studies</p> </section> </section> <section id="CD009396-sec-0039"> <h5 class="title">Secondary outcomes</h5> <section id="CD009396-sec-0040"> <h6 class="title">1. Mental state: symptoms of schizophrenia</h6> <p>1.1 Overall symptoms ‐ average score/change in general mental state<br/> 1.2 Positive symptoms ‐ average score/change in positive symptoms<br/> 1.3 Negative symptoms ‐ average score/change in negative symptoms </p> </section> <section id="CD009396-sec-0041"> <h6 class="title">2. Global state: average score/change in global state</h6> </section> <section id="CD009396-sec-0042"> <h6 class="title">3. Leaving the study early</h6> <p>3.1 Acceptability of treatment ‐ leaving the study early due to any reason<br/> 3.2 Leaving the study early due to inefficacy of treatment<br/> 3.3 Leaving the study early due to side‐effects </p> </section> <section id="CD009396-sec-0043"> <h6 class="title">4. Relapse ‐ as defined by each of the studies</h6> </section> <section id="CD009396-sec-0044"> <h6 class="title">5. Service use</h6> <p>5.1 Rehospitalisation</p> </section> <section id="CD009396-sec-0045"> <h6 class="title">6. Adverse effects</h6> <p>6.1 At least one adverse effect<br/> 6.2 Extrapyramidal/movement disorders<br/> 6.2.1 At least one movement disorder<br/> 6.2.2. Various movement disorders<br/> 6.3 Cardiac effects<br/> 6.4 Hypotension<br/> 6.5 Sedation<br/> 6.6 Weight gain<br/> 6.7 Other </p> </section> <section id="CD009396-sec-0046"> <h6 class="title">7. Death</h6> <p>7.1 Death (all causes)<br/> 7.2 Suicide </p> </section> <section id="CD009396-sec-0047"> <h6 class="title">8. Quality of life</h6> </section> <section id="CD009396-sec-0048"> <h6 class="title">9. Participant's/carer`s satisfaction with care</h6> </section> <section id="CD009396-sec-0049"> <h6 class="title">10. Economic outcomes</h6> <p>Outcomes were classified into short term (up to 12 weeks), medium term (up to 26 weeks) and long term (longer than 26 weeks). </p> </section> </section> </section> </section> <section id="CD009396-sec-0050"> <h3 class="title">Search methods for identification of studies</h3> <p>No language restriction was applied</p> <section id="CD009396-sec-0051"> <h4 class="title">Electronic searches</h4> <section id="CD009396-sec-0052"> <h5 class="title">Cochrane Schizophrenia Group's Trials Register (November 2010)</h5> <p>We searched the register using the phrase:</p> <p>[(*trifluoperazine* in intervention of STUDY) OR (*trifluoperazine* in title, abstract and index terms of REFERENCE entered &gt;= 01/05/10)] </p> <p>This register is compiled by systematic searches of major databases, clinical trial registries, handsearches and conference proceedings (see <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/SCHIZ/frame.html" target="_blank">Group Module</a>). </p> </section> </section> <section id="CD009396-sec-0053"> <h4 class="title">Searching other resources</h4> <section id="CD009396-sec-0054"> <h5 class="title">1. Reference searching</h5> <p>We inspected the references of all identified included studies for more trials.</p> </section> <section id="CD009396-sec-0055"> <h5 class="title">2. Previous reviews</h5> <p>We searched previous conventional reviews (e.g. <a href="./references#CD009396-bbs2-0043" title="DavisJM , BarterJT , KaneJM . Antipsychotic drugs. Comprehensive Textbook of Psychiatry. Williams and Wilkins, 1989. ">Davis 1989</a>; <a href="./references#CD009396-bbs2-0059" title="KleinDF , DavisJM . Diagnosis and Drug Treatment of Psychiatric Disorders. Baltimore: Williams and Wilkins, 1969. ">Klein 1969</a>). </p> </section> <section id="CD009396-sec-0056"> <h5 class="title">3. Personal contact</h5> <p>We contacted the first author of each included study for missing information and for the existence of further studies. </p> </section> <section id="CD009396-sec-0057"> <h5 class="title">4. Drug companies</h5> <p>We contacted the original manufacturer of trifluoperazine and asked for further relevant studies and for missing information on identified studies. </p> </section> </section> </section> <section id="CD009396-sec-0058"> <h3 class="title" id="CD009396-sec-0058">Data collection and analysis</h3> <section id="CD009396-sec-0059"> <h4 class="title">Selection of studies</h4> <p>Review authors (MT, MD) independently inspected all abstracts identified in the searches. Disagreement was resolved by discussion and where doubt still remained, we acquired the full article for further inspection. Once the full articles were obtained, at least two review authors independently decided whether the studies met the review criteria. If disagreement could not be resolved by discussion, we resolved it with a third review author (SL) or sought further information from the study authors. </p> </section> <section id="CD009396-sec-0060"> <h4 class="title">Data extraction and management</h4> <section id="CD009396-sec-0061"> <h5 class="title">1. Extraction</h5> <p>Originally two review authors (MT, MD) independently extracted data from all selected trials. We decided post‐hoc to include all outcomes reported by a study, not only the predefined outcomes in the methods section. For the outcomes added post‐hoc only a random sample of 25% were independently extracted by a second review authors (MH, see <a href="#CD009396-sec-0185">Acknowledgements</a>). When disagreement arose, we resolved it by discussion with a third review author (SL). Where this was not possible, we contacted the study authors to resolve the dilemma. </p> </section> <section id="CD009396-sec-0062"> <h5 class="title">2. Management</h5> <section id="CD009396-sec-0063"> <h6 class="title">2.1 Forms</h6> <p>We extracted data onto simple standard forms.</p> </section> <section id="CD009396-sec-0064"> <h6 class="title">2.2 Scale‐derived data</h6> <p>If reported, we planned to include continuous data from rating scales only if: (a) the psychometric properties of the measuring instrument had been described in a peer‐reviewed journal (<a href="./references#CD009396-bbs2-0067" title="MarshallM , LockwoodA , BradleyC , AdamsC , JoyC , FentonM . Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry2000;176:249‐52. ">Marshall 2000</a>); (b) the measuring instrument was not written or modified by one of the trialists. </p> </section> <section id="CD009396-sec-0065"> <h6 class="title">2.3 Endpoint versus change data</h6> <p>Since there is no principal statistical reason why endpoint and change data should measure different effects (<a href="./references#CD009396-bbs2-0056" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>), we decided primarily to use scale endpoint data. If endpoint data were not available we used change data. </p> </section> <section id="CD009396-sec-0066"> <h6 class="title">2.4 Skewed data</h6> <p>Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non‐parametric data, we applied the following standards to all data before inclusion: (a) data from studies of at least 200 participants were entered in the analysis irrespective of the following rules, because skewed data pose less of a problem in large studies; (b) endpoint data: when a scale starts from the finite number zero, we subtracted the lowest possible value from the mean, and divided this by the standard deviation (SD). If this value was lower than one, it strongly suggested a skew and the study was excluded. If this ratio was higher than one but below two, there is suggestion of skew. We entered the study and tested whether its inclusion or exclusion substantially changed the results. If the ratio was larger than two the study was included, because skew is less likely (<a href="./references#CD009396-bbs2-0035" title="AltmanDG , BlandJM . Detecting skewness from summary information. BMJ1996;313:1200. ">Altman 1996</a>; <a href="./references#CD009396-bbs2-0055" title=" HigginsJPT , DeeksJJ , Altman DG(editors) . Chapter 16: Special topics in statistics. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (updated September 2008). The Cochrane Collaboration, 2008:481‐524. ">Higgins 2008</a>); (c) change data: when continuous data are presented on a scale which includes a possibility of negative values (such as change data), it is difficult to tell whether data are skewed or not. We entered the study, because change data tend to be less skewed and because excluding studies would also lead to bias, since not all the available information was used. </p> </section> <section id="CD009396-sec-0067"> <h6 class="title">2.5 Common measure</h6> <p>To facilitate comparison between trials, we intended to convert variables that can be reported in different metrics, such as days in hospital (mean days per year, per week or per month) to a common metric (e.g. mean days per month). </p> </section> <section id="CD009396-sec-0068"> <h6 class="title">2.6 'Summary of findings' table</h6> <p>We used the GRADE approach to interpret findings (<a href="./references#CD009396-bbs2-0072" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , GuyattGH . Chapter 12: Interpreting results and drawing conclusions. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2008:359‐83. ">Schünemann 2008</a>) and used GRADE profiler (<a href="http://www.ims.cochrane.org/revman/gradepro" target="_blank">GRADE</a>) to import data from RevMan 5 (<a href="http://www.ims.cochrane.org/revman" target="_blank">Review Manager</a>) to create <a href="./full#CD009396-tbl-0001">summary of findings Table for the main comparison</a>. This table provides outcome‐specific information concerning the overall quality of evidence from each included study in the comparison, the magnitude of effect of the interventions examined, and the sum of available data on all outcomes we rated as important to patient‐care and decision making. We selected the following long‐term main outcomes for inclusion in the 'Summary of findings' table. </p> <p> <ol id="CD009396-list-0001"> <li> <p>Response to treatment</p> </li> <li> <p>Acceptability of treatment ‐ leaving the study early due to any reason</p> </li> <li> <p>Adverse effects ‐ at least one adverse effect</p> </li> <li> <p>Adverse effects ‐ at least one extrapyramidal side‐effect</p> </li> <li> <p>Adverse effects ‐ sedation</p> </li> <li> <p>Death</p> </li> <li> <p>Quality of life</p> </li> </ol> </p> </section> </section> </section> <section id="CD009396-sec-0069"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Review authors MT, MD worked independently by using criteria described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009396-bbs2-0056" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>) to assess trial quality. This new set of criteria is based on evidence of associations between overestimate of effect and high risk of bias due to mistakes in sequence generation, allocation concealment, blinding, incomplete outcome data and selective reporting. </p> <p>Disagreements, if any, were resolved by referring to the trial report, correspondence with the authors of the report and through discussions.and involvement of another member of the review group (SL). We reported any quality assessments where there was lack of agreement between raters. </p> <p>Where inadequate details of randomisation and other characteristics of trials were provided, we contacted the authors of the studies in order to obtain additional information. </p> <p>We have noted the level of risk of bias in both the text of the review and in the <a href="./full#CD009396-tbl-0001">summary of findings Table for the main comparison</a>. </p> </section> <section id="CD009396-sec-0070"> <h4 class="title">Measures of treatment effect</h4> <section id="CD009396-sec-0071"> <h5 class="title">1. Dichotomous data</h5> <p>For binary outcomes we calculated a standard estimation of the random‐effects (<a href="./references#CD009396-bbs2-0045" title="Der‐SimonianR , LairdN . Meta‐analysis in clinical trials. Controlled Clinical Trials1986;7:177‐88. ">Der‐Simonian 1986</a>) risk ratio (RR) and its 95% confidence interval (CI). It has been shown that RR is more intuitive (<a href="./references#CD009396-bbs2-0039" title="BoisselJP , CucheratM , LiW , ChatellierG , GueyffierF , BuyseM , et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use. Therapie1999;54(4):405‐11. ">Boissel 1999</a>) than odds ratios and that odds ratios tend to be interpreted as RR by clinicians (<a href="./references#CD009396-bbs2-0044" title="DeeksJ . Issues in the selection for meta‐analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25‐28th; Cape Town, South Africa. Cape Town, 2000. ">Deeks 2000</a>). This misinterpretation then leads to an overestimate of the impression of the effect. Where possible, efforts were made to convert outcome measures to dichotomous data. This could be done by identifying cut‐off points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. It was generally assumed that if there had been a 50% reduction in a scale‐derived score such as the Brief Psychiatric Rating Scale (BPRS, <a href="./references#CD009396-bbs2-0070" title="OverallJE , GorhamDR . The brief psychiatric rating scale. Psychological Reports1962;10:799‐12. ">Overall 1962</a>) or the Positive and Negative Syndrome Scale (PANSS, <a href="./references#CD009396-bbs2-0058" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) manual. North Tonawanda (NY): Multi‐Health Systems, 1986. ">Kay 1986</a>), this could be considered as a response to treatment (<a href="./references#CD009396-bbs2-0062" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelR . What does the PANSS mean?. Schizophrenia Research2005;79:231‐8. ">Leucht 2005a</a>; <a href="./references#CD009396-bbs2-0063" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelR . Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry2005;187:366‐71. ">Leucht 2005b</a>). If data based on these thresholds were not available, we used the primary cut‐off presented by the original authors. </p> </section> <section id="CD009396-sec-0072"> <h5 class="title">2. Continuous data</h5> <p>If continuous data been reported, we would have estimated a mean difference (MD) between groups. If scales were of such similarity to allow pooling we would have calculated the standardised mean difference (SMD) and, whenever possible, transformed the effect back to the units of one or more of the specific instruments. </p> </section> </section> <section id="CD009396-sec-0073"> <h4 class="title">Unit of analysis issues</h4> <section id="CD009396-sec-0074"> <h5 class="title">1. Cluster trials</h5> <p>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice) but analysis and pooling of clustered data poses problems. Firstly, authors often fail to account for intraclass correlation in clustered studies, leading to a 'unit of analysis' error (<a href="./references#CD009396-bbs2-0046" title="DivineGW , BrownJT , FrazerLM . The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine1992;7:623‐9. ">Divine 1992</a>) whereby P values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated. This causes type I errors (<a href="./references#CD009396-bbs2-0038" title="BlandJM , KerrySM . Statistics notes. Trials randomised in clusters. BMJ1997;315:600. ">Bland 1997</a>; <a href="./references#CD009396-bbs2-0052" title="GullifordMC , UkoumunneOC , ChinnS . Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology1999;149:876‐83. ">Gulliford 1999</a>). </p> <p>If we had included cluster randomised trials and if results from trials had not adjusted for clustering, we would have attempted to adjust the results for clustering, by multiplying the standard errors of the effect estimates (risk ratio or mean difference, ignoring clustering) by the square root of the design effect. The design effect is calculated as D<sub>Eff</sub> =1 + (M ‐ 1) ICC, where M is the average cluster size and ICC is the intra‐cluster coefficient (<a href="./references#CD009396-bbs2-0055" title=" HigginsJPT , DeeksJJ , Altman DG(editors) . Chapter 16: Special topics in statistics. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (updated September 2008). The Cochrane Collaboration, 2008:481‐524. ">Higgins 2008</a>). If an ICC was not available from the trial, other sources would have been used to impute ICCs (<a href="./references#CD009396-bbs2-0040" title="CampbellM , GrimshawJ , SteenN . Sample size calculations for cluster randomised trials. Changing Professional Practice in Europe Group (EU BIOMED II Concerted Action). Journal of Health Services Research and Policy2000;5:12‐6. ">Campbell 2000</a>). </p> <p>If clustering had been incorporated into the analysis of primary studies, we would have presented these data as if from a non‐cluster randomised study, but adjusted for the clustering effect. If a cluster study had been appropriately analysed taking into account ICC and relevant data documented in the report, synthesis with parallel group randomised trials would have been possible using the generic inverse variance technique, where the natural logarithm of the effect estimate (and standard errors) for all included trials for that outcome would be calculated and entered into <a href="http://www.ims.cochrane.org/revman" target="_blank">RevMan</a> along with the log of the effect estimate (and standard errors) from the cluster randomised trial(s). We would have used methods described in section 7.7.7.2 and 7.7.7.3 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009396-bbs2-0055" title=" HigginsJPT , DeeksJJ , Altman DG(editors) . Chapter 16: Special topics in statistics. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (updated September 2008). The Cochrane Collaboration, 2008:481‐524. ">Higgins 2008</a>) to obtain standard errors. </p> </section> <section id="CD009396-sec-0075"> <h5 class="title">2. Cross‐over trials</h5> <p>A major concern of cross‐over trials is the carry‐over effect. It occurs if an effect (e.g. pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence, on entry to the second phase the participants can differ systematically from their initial state despite a wash‐out phase. For the same reason cross‐over trials are not appropriate if the condition of interest is unstable (<a href="./references#CD009396-bbs2-0048" title="ElbourneDR , AltmanDG , HigginsJP , CurtinF , WorthingtonHV , VailA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31:140‐9. ">Elbourne 2002</a>). As both effects are very likely in schizophrenia, randomised cross‐over studies were eligible but only data up to the point of first cross‐over were used for analysis. </p> </section> </section> <section id="CD009396-sec-0076"> <h4 class="title">Dealing with missing data</h4> <section id="CD009396-sec-0077"> <h5 class="title">1. Overall loss of credibility</h5> <p>At some degree of loss of follow‐up, data must lose credibility (<a href="./references#CD009396-bbs2-0081" title="XiaJ , AdamsCE , BhagatN , BhagatV , BhoopathiP , El‐SayehH , et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin2009;33(7):254‐7. ">Xia 2009</a>). The loss to follow‐up in randomised schizophrenia trials is often considerable calling the validity of the results into question. Nevertheless, it is unclear which degree of attrition leads to a high degree of bias. We did not exclude trials from outcomes on the basis of the percentage of participants completing them. We, however, used the 'Risk of bias' tool described above to indicate potential bias when more than 25% of the participants left the studies prematurely, when the reasons for attrition differed between the intervention and the control group, and when no appropriate imputation strategies were applied. </p> </section> <section id="CD009396-sec-0078"> <h5 class="title">2. Dichotomous data</h5> <p>Data were presented on a 'once‐randomised‐always‐analyse' basis, assuming an intention‐to‐treat analysis. If the authors applied such a strategy, we used their results. If the original authors presented only the results of the per‐protocol or completer population, we assumed that those participants lost to follow‐up would have had the same percentage of events as those who remained in the study. </p> </section> <section id="CD009396-sec-0079"> <h5 class="title">3. Continuous data</h5> <section id="CD009396-sec-0080"> <h6 class="title">3.1 General</h6> <p>Intention‐to‐treat (ITT) was used when available. We anticipated that in some studies, in order to do an ITT analysis, the method of last observation carried forward (LOCF) would be employed within the study report. As with all methods of imputation to deal with missing data, LOCF introduces uncertainty about the reliability of the results (<a href="./references#CD009396-bbs2-0061" title="LeonAC , MallinckrodtCH , Chuang‐SteinC , ArchibaldDG , ArcherGE , ChartierK . Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology. Biological Psychiatry2006;59:1001‐5. ">Leon 2006</a>). Therefore, if LOCF data had been used in the analysis, we would have indicated this in the review. </p> </section> <section id="CD009396-sec-0081"> <h6 class="title">3.2 Missing standard deviations</h6> <p>Where there are missing measures of variance for continuous data but an exact standard error and confidence interval are available for group means, and either ‘P’ value or 't' value are available for differences in mean, we can calculate standard deviation values according to method described in Section 7.7.3 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009396-bbs2-0056" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>). If standard deviations were not reported and could not be calculated from available data, we asked authors to supply the data. In the absence of data from authors, we used the mean standard deviation from other studies. </p> </section> </section> </section> <section id="CD009396-sec-0082"> <h4 class="title">Assessment of heterogeneity</h4> <section id="CD009396-sec-0083"> <h5 class="title">1. Clinical</h5> <p>We considered all included studies without any comparison to judge clinical heterogeneity.</p> <p>We inspected all studies for clearly outlying situations or people which we had not predicted would arise and discussed them fully, if such situations or participants arose. </p> </section> <section id="CD009396-sec-0084"> <h5 class="title">2. Methodological</h5> <p>We considered all included studies initially, without seeing comparison data, to judge methodological heterogeneity. We inspected all studies for clearly outlying methods which we had not predicted would arise and discussed them if they were evident. </p> </section> <section id="CD009396-sec-0085"> <h5 class="title">3. Statistical</h5> <section id="CD009396-sec-0086"> <h6 class="title">3.1 Visual inspection</h6> <p>We visually inspected graphs to identify trials with non‐overlapping confidence intervals within a forest plot to suggest the possibility of statistical heterogeneity. </p> </section> <section id="CD009396-sec-0087"> <h6 class="title">3.2 Employing the I<sup>2</sup>statistic </h6> <p>Heterogeneity between studies was investigated by considering the I<sup>2</sup> method alongside the Chi<sup>2</sup> 'P' value. The I<sup>2</sup> provides an estimate of the percentage of inconsistency thought to be due to chance (<a href="./references#CD009396-bbs2-0056" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>). The importance of the observed value of I<sup>2</sup> depends on i. magnitude and direction of effects and ii. strength of evidence for heterogeneity (e.g. 'P' value from Chi<sup>2</sup> test, or a confidence interval for I<sup>2</sup>). </p> <p>An I<sup>2</sup> estimate greater than or equal to 50% accompanied by a statistically significant Chi<sup>2</sup> statistic, was interpreted as evidence of substantial levels of heterogeneity (Section 9.5.2 <i>Cochrane Handbook for Systematic Reviews of Interventions</i> ‐ <a href="./references#CD009396-bbs2-0056" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>) and reasons for heterogeneity were explored. If the inconsistency was high and the clear reasons were found, data were presented separately. </p> </section> </section> </section> <section id="CD009396-sec-0088"> <h4 class="title">Assessment of reporting biases</h4> <p>We intended to enter data from all identified and selected trials for each outcome into a funnel plot (trial effect versus trial size) in an attempt to investigate the likelihood of overt publication bias. We planned to test for funnel plot asymmetry only for outcomes where there were 10 or more studies and if the studies were not of similar sizes, as recommended in Section 10.4.3.1 of the Cochrane Handbook (<a href="./references#CD009396-bbs2-0056" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>). If outcomes with more than 10 studies had been available, we would have used the statistical test by Egger (<a href="./references#CD009396-bbs2-0047" title="EggerM , Davey‐SmithG , SchneiderM , MinderCSO . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;13:629‐34. ">Egger 1997</a>) to formally assess funnel‐plot asymmetry, and supplement visual inspection of the forest plot to differentiate small‐study effects from other reasons for funnel plot asymmetry. </p> </section> <section id="CD009396-sec-0089"> <h4 class="title">Data synthesis</h4> <p>We employed a random‐effects model for analyses (<a href="./references#CD009396-bbs2-0045" title="Der‐SimonianR , LairdN . Meta‐analysis in clinical trials. Controlled Clinical Trials1986;7:177‐88. ">Der‐Simonian 1986</a>). We understand that there is no closed argument for preference for use of fixed‐effect or random‐effects models. The random‐effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. This does seem true to us and the random‐effects model takes into account differences between studies, even if there is no statistically significant heterogeneity. Therefore, the random‐effects model is usually more conservative in terms of statistical significance, although as a disadvantage it puts added weight onto smaller studies which can either inflate or deflate the effect size. We examined in a sensitivity analysis whether using a fixed‐effect model markedly changed the results of the primary outcome. </p> </section> <section id="CD009396-sec-0090"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <section id="CD009396-sec-0091"> <h5 class="title">1. Subgroup analysis</h5> <p>Subgroup analyses were applied only to the primary outcome.</p> <section id="CD009396-sec-0092"> <h6 class="title">1.1 Comparison drug</h6> <p>In order to reduce clinical and methodological reasons for heterogeneity, we subgrouped trials that compared trifluoperazine versus each single low‐potency antipsychotic separately. </p> </section> <section id="CD009396-sec-0093"> <h6 class="title">1.2 Clinical state, stage or problem</h6> <p>We proposed to undertake this review and provide an overview of the effects of trifluoperazine for people with schizophrenia in general. In addition, however, we tried to report data on subgroups of people in the same clinical state, stage and with similar problems but data were not available. </p> </section> </section> <section id="CD009396-sec-0094"> <h5 class="title">2. Investigation of heterogeneity</h5> <p>When statistical heterogeneity was detected and quantified as significant, we noted whether significant heterogeneity was present within the subgroups. If unanticipated clinical or methodological heterogeneity was evident among the trials in the subgroups, or in the pooled results, we stated hypotheses regarding these for future reviews or versions of this review. We did not undertake further analyses relating to these hypotheses. </p> </section> </section> <section id="CD009396-sec-0095"> <h4 class="title">Sensitivity analysis</h4> <p>Sensitivity analyses were only applied to the primary outcome.</p> <section id="CD009396-sec-0096"> <h5 class="title">1. Risk of bias</h5> <p>We analysed the effects of excluding trials that were judged to be at high risk of bias across one or more of the domains of randomisation (implied as randomised with no further details available) allocation concealment, blinding and outcome reporting for the meta‐analysis of the primary outcome. If the exclusion of trials at high risk of bias did not substantially alter the direction of effect or the precision of the effect estimates, then data from these trials were included in the analysis. </p> </section> <section id="CD009396-sec-0097"> <h5 class="title">2. Assessment of dosage</h5> <p>We included trials in a sensitivity analysis if doses between high‐potency and low‐potency antipsychotics were clearly discrepant by our judgement based on the chlorpromazine equivalence tables by <a href="./references#CD009396-bbs2-0042" title="DavisJM . Overview: maintenance therapy in psychiatry: I. Schizophrenia. American Journal of Psychiatry1975;132(12):1237‐45. ">Davis 1974</a>, <a href="./references#CD009396-bbs2-0053" title="HaaseHJ . Dosierung der Neuroleptika. Ein Leitfaden für Klinik und Praxis unter besonderer Berücksichtigung psychotisch Kranker. Erlangen: Perimed Fachbuch‐Verlagsgesellschaft, 1983. ">Haase 1983</a> and <a href="./references#CD009396-bbs2-0036" title="AndreasenNC , PresslerM , NopoulosP , MillerD , HoBC . Antipsychotic dose equivalents and dose‐years: a standardized method for comparing exposure to different drugs. Biological Psychiatry2010;67:255‐62. ">Andreasen 2010</a>. If there was no substantive difference when studies with discrepant doses were added, then all data were employed. </p> </section> <section id="CD009396-sec-0098"> <h5 class="title">3. Imputed values</h5> <p>If we had included cluster randomised trials, we planned to undertake a sensitivity analysis to assess the effects of including data from trials where we used imputed values for ICC in calculating the design effect in cluster randomised trials. </p> <p>If substantial differences were noted in the direction or precision of effect estimates in any of the sensitivity analyses listed above, we did not pool data from the excluded trials with the other trials contributing to the outcome, but presented them separately </p> </section> <section id="CD009396-sec-0099"> <h5 class="title">4. Fixed and random effects</h5> <p>We synthesised data for the primary outcome using a fixed‐effect model to evaluate whether the greater weights assigned to larger trials with greater event rates altered the significance of the results, compared to the more evenly distributed weights in the random‐effects model. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD009396-sec-0100" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD009396-sec-0100"></div> <section id="CD009396-sec-0101"> <h3 class="title">Description of studies</h3> <p>For substantive description of studies please see <a href="./references#CD009396-sec-0194" title="">Characteristics of included studies</a> and <a href="./references#CD009396-sec-0195" title="">Characteristics of excluded studies</a> tables. </p> <section id="CD009396-sec-0102"> <h4 class="title">Results of the search</h4> <p>The search in the Cochrane Schizophrenia Group register yielded 216 references from which 181 studies were identified and screened. Thirty‐four studies were closely inspected. Eight publications on seven studies were included and 27 publications reporting on 27 studies were excluded (see <a href="#CD009396-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD009396-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD009396-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/image_n/nCD009396-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD009396-sec-0103"> <h4 class="title">Included studies</h4> <p>Seven studies (422 participants) met the inclusion criteria.</p> <section id="CD009396-sec-0104"> <h5 class="title">1. Length of trials</h5> <p>Of the included studies, one study had a duration up to one month and two a duration up to three months. Two studies had a duration up to four months, one study lasted up to six months and one study up to 12 months. </p> </section> <section id="CD009396-sec-0105"> <h5 class="title">2. Participants</h5> <p>In five included studies, participants were diagnosed according to clinical diagnoses. One study diagnosed according to the Present State Examination (<a href="./references#CD009396-bbs2-0004" title="LeffJP , HirschSR , GaindR , RohdePD , StevensBC . Life events and maintenance therapy in schizophrenic relapse. British Journal of Psychiatry1973;123:659‐60. LeffJP , WingJK . Trial of maintenance therapy in schizophrenia. British Medical Journal1971;3:599‐604. ">Leff 1971</a>), one study diagnosed participants according to Bleuler´s concept (<a href="./references#CD009396-bbs2-0006" title="ReardonJD , AbramsS . Acute paranoid schizophrenia (treatment with chlorpromazine, trifluoperazine and placebo). Diseases of the Nervous System1966;27:265‐70. ">Reardon 1966</a>). </p> </section> <section id="CD009396-sec-0106"> <h5 class="title">3. Setting</h5> <p>Four studies were conducted in hospitals and one study included outpatients. Two studies (<a href="./references#CD009396-bbs2-0001" title="CoonsWH , BoydBA , WhiteJG . Chlorpromazine, trifluoperazine and placebo with long‐term mental hospital patients. Canadian Psychiatric Association Journal1962;7(4):159‐63. ">Coons 1962</a>; <a href="./references#CD009396-bbs2-0003" title="HollisterLE , EricksonGV , MotzenteckerFP . Trifluoperazine in chronic psychiatric patients. Journal of Clinical and Experimental Psychopathology 19610;21:15‐23. ">Hollister 1960</a>) did not report on setting. </p> </section> <section id="CD009396-sec-0107"> <h5 class="title">4. Study size</h5> <p><a href="./references#CD009396-bbs2-0002" title="HanlonTE , MichauxMH , OtaKY , ShafferJW , KurlandAA . The comparative effectiveness of eight phenthiazines. Psychopharmacologia1965;7:89‐106. ">Hanlon 1965</a> was the largest study with 157 participants, followed by <a href="./references#CD009396-bbs2-0001" title="CoonsWH , BoydBA , WhiteJG . Chlorpromazine, trifluoperazine and placebo with long‐term mental hospital patients. Canadian Psychiatric Association Journal1962;7(4):159‐63. ">Coons 1962</a> with 103 participants. <a href="./references#CD009396-bbs2-0004" title="LeffJP , HirschSR , GaindR , RohdePD , StevensBC . Life events and maintenance therapy in schizophrenic relapse. British Journal of Psychiatry1973;123:659‐60. LeffJP , WingJK . Trial of maintenance therapy in schizophrenia. British Medical Journal1971;3:599‐604. ">Leff 1971</a> and <a href="./references#CD009396-bbs2-0005" title="MortonMR . A study of the withdrawal of chlorpromazine or trifluoperazine in chronic schizophrenia. American Journal of Psychiatry1968;124(11):1585‐8. ">Morton 1968</a> were the smallest studies, each randomising only 20 participants with schizophrenia. Three further studies randomised between 30 and 80 participants. </p> </section> <section id="CD009396-sec-0108"> <h5 class="title">5. Interventions</h5> <p>All studies compared trifluoperazine and low‐potency antipsychotics. In most studies flexible doses of antipsychotic drugs could be applied. The dose ranges were: 100‐1800 mg/day for chlorpromazine, 100 to 1000 mg/day for thioridazine and 2 to 50 mg/day for trifluoperazine. In two studies various low‐potency antipsychotics could be administered (<a href="./references#CD009396-bbs2-0002" title="HanlonTE , MichauxMH , OtaKY , ShafferJW , KurlandAA . The comparative effectiveness of eight phenthiazines. Psychopharmacologia1965;7:89‐106. ">Hanlon 1965</a>; <a href="./references#CD009396-bbs2-0007" title="SchieleBC , VestreND , SteinKE . A comparison of thioridazine, trifluoperazine, chlorpromazine, and placebo: a double‐blind controlled study on the treatment of chronic hospitalized, schizophrenic patients. Journal of Clinical and Experimental Psychopathology1961;22:151‐62. ">Schiele 1961</a>). </p> </section> <section id="CD009396-sec-0109"> <h5 class="title">6. Outcomes</h5> <section id="CD009396-sec-0110"> <h6 class="title">6.1 Response to treatment</h6> <p>Our primary outcome was response to treatment as defined by the original studies. Different definitions were used. In one study (<a href="./references#CD009396-bbs2-0003" title="HollisterLE , EricksonGV , MotzenteckerFP . Trifluoperazine in chronic psychiatric patients. Journal of Clinical and Experimental Psychopathology 19610;21:15‐23. ">Hollister 1960</a>), the ward psychiatrist decided whether patients had responded or not. <a href="./references#CD009396-bbs2-0005" title="MortonMR . A study of the withdrawal of chlorpromazine or trifluoperazine in chronic schizophrenia. American Journal of Psychiatry1968;124(11):1585‐8. ">Morton 1968</a> applied an overall clinical assessment with the Wing scale (<a href="./references#CD009396-bbs2-0080" title="WingJK . A simple and reliable subclassification of chronic schizophrenia. Journal of Mental Science1961;107:862–75. ">Wing 1961</a>, see below) and combined this with the raters' general clinical impressions. <a href="./references#CD009396-bbs2-0007" title="SchieleBC , VestreND , SteinKE . A comparison of thioridazine, trifluoperazine, chlorpromazine, and placebo: a double‐blind controlled study on the treatment of chronic hospitalized, schizophrenic patients. Journal of Clinical and Experimental Psychopathology1961;22:151‐62. ">Schiele 1961</a> used the Minnesota Multiphasic Personality Inventory (<a href="./references#CD009396-bbs2-0054" title="Hathaway , SR , McKinley , JC . A multiphasic personality schedule (Minnesota). Journal of Psychology1940;10:249‐54. ">Hathaway 1940</a>, see below). </p> </section> <section id="CD009396-sec-0111"> <h6 class="title">6.2 Relapse</h6> <p>Five of the included studies reported data on relapse (<a href="./references#CD009396-bbs2-0003" title="HollisterLE , EricksonGV , MotzenteckerFP . Trifluoperazine in chronic psychiatric patients. Journal of Clinical and Experimental Psychopathology 19610;21:15‐23. ">Hollister 1960</a>; <a href="./references#CD009396-bbs2-0004" title="LeffJP , HirschSR , GaindR , RohdePD , StevensBC . Life events and maintenance therapy in schizophrenic relapse. British Journal of Psychiatry1973;123:659‐60. LeffJP , WingJK . Trial of maintenance therapy in schizophrenia. British Medical Journal1971;3:599‐604. ">Leff 1971</a>; <a href="./references#CD009396-bbs2-0005" title="MortonMR . A study of the withdrawal of chlorpromazine or trifluoperazine in chronic schizophrenia. American Journal of Psychiatry1968;124(11):1585‐8. ">Morton 1968</a>; <a href="./references#CD009396-bbs2-0006" title="ReardonJD , AbramsS . Acute paranoid schizophrenia (treatment with chlorpromazine, trifluoperazine and placebo). Diseases of the Nervous System1966;27:265‐70. ">Reardon 1966</a>; <a href="./references#CD009396-bbs2-0007" title="SchieleBC , VestreND , SteinKE . A comparison of thioridazine, trifluoperazine, chlorpromazine, and placebo: a double‐blind controlled study on the treatment of chronic hospitalized, schizophrenic patients. Journal of Clinical and Experimental Psychopathology1961;22:151‐62. ">Schiele 1961</a>). </p> </section> <section id="CD009396-sec-0112"> <h6 class="title">6.3 Leaving the study early</h6> <p>The number of participants leaving the study early were recorded for the categories any reason, adverse events and lack of efficacy. Three out of seven included studies reported on this outcome (<a href="./references#CD009396-bbs2-0002" title="HanlonTE , MichauxMH , OtaKY , ShafferJW , KurlandAA . The comparative effectiveness of eight phenthiazines. Psychopharmacologia1965;7:89‐106. ">Hanlon 1965</a>; <a href="./references#CD009396-bbs2-0006" title="ReardonJD , AbramsS . Acute paranoid schizophrenia (treatment with chlorpromazine, trifluoperazine and placebo). Diseases of the Nervous System1966;27:265‐70. ">Reardon 1966</a>; <a href="./references#CD009396-bbs2-0007" title="SchieleBC , VestreND , SteinKE . A comparison of thioridazine, trifluoperazine, chlorpromazine, and placebo: a double‐blind controlled study on the treatment of chronic hospitalized, schizophrenic patients. Journal of Clinical and Experimental Psychopathology1961;22:151‐62. ">Schiele 1961</a>). </p> </section> <section id="CD009396-sec-0113"> <h6 class="title">6.4 Service use</h6> <p>None of the included studies reported data on this outcome.</p> </section> <section id="CD009396-sec-0114"> <h6 class="title">6.5 Adverse effects</h6> <p>The following adverse effects 'at least one adverse event', at least one movement disorder, akathisia, akinesia, dyskinesia, incoordination, rigor, atypical seizure, blurred vision, decreased appetite, dizziness, drooling, drowsiness, insomnia, lethargy, muscle weakness, polydipsia, polyuria, skin disorder, syncope, slurred speech and tenseness were reported in a dichotomous manner in terms of the number of participants with a given side‐effect. </p> </section> <section id="CD009396-sec-0115"> <h6 class="title">6.6 Missing outcomes</h6> <p>None of the included studies reported data on death, sedation, weight gain, quality of life, participant´s satisfaction with care and economic outcomes. </p> </section> <section id="CD009396-sec-0116"> <h6 class="title">6.7 Scale data</h6> <p>The presentation of scale derived data was very poor. Mean values could not be used. The following scales were used by the original authors to classify participants as responders and non‐responders. </p> <p>6.7.1 Wing scale (<a href="./references#CD009396-bbs2-0080" title="WingJK . A simple and reliable subclassification of chronic schizophrenia. Journal of Mental Science1961;107:862–75. ">Wing 1961</a>) </p> <p>A symptom rating scale, measuring affect, speech and delusions. High scores mean more symptoms. </p> <p>6.7.2 Minnesota Multiphasic Personality Inventory (<a href="./references#CD009396-bbs2-0054" title="Hathaway , SR , McKinley , JC . A multiphasic personality schedule (Minnesota). Journal of Psychology1940;10:249‐54. ">Hathaway 1940</a>) </p> <p>A personality test in mental health. <a href="./references#CD009396-bbs2-0007" title="SchieleBC , VestreND , SteinKE . A comparison of thioridazine, trifluoperazine, chlorpromazine, and placebo: a double‐blind controlled study on the treatment of chronic hospitalized, schizophrenic patients. Journal of Clinical and Experimental Psychopathology1961;22:151‐62. ">Schiele 1961</a> used it for the classification into responders and non‐responders, but the exact procedure remained unclear. </p> </section> </section> </section> <section id="CD009396-sec-0117"> <h4 class="title">Excluded studies</h4> <p>Twenty‐seven studies were excluded from the analysis. Six studies were excluded because of inadequate allocation, they were not randomised (<a href="./references#CD009396-bbs2-0008" title="BarsaJA , SaundersJC , KlineNS . Trifluoperazine in the treatment of chronic schizophrenics. American Journal of Psychiatry1959;115(9):812. ">Barsa 1959</a>; <a href="./references#CD009396-bbs2-0010" title="ChildersRT , TherrienR . A comparison of the effectiveness of trifluoperazine and chlorpromazine in schizophrenia. American Journal of Psychiatry1964;118:552‐4. ">Childers 1964</a>; <a href="./references#CD009396-bbs2-0015" title="FreyhanFA . Therapeutic implications of differential effects of new phenothiazine compounds. American Journal of Psychiatry1959;116:577‐85. ">Freyhan 1959</a>; <a href="./references#CD009396-bbs2-0017" title="GillisJS . The effects of selected antipsychotic drugs of human judgment. Current Therapeutic Research, Clinical and Experimental1977;21(2):224‐32. ">Gillis 1977</a>; <a href="./references#CD009396-bbs2-0029" title="TerminskaK , MrowiecW . Comparison of influence of perazine, fluphenazine, trifluoroperazine, chloropromazine and haloperidol on primary and deficit schizophrenic symptoms in patients first hospitalized because of paranoid schizophrenia [Badanie porownawcze wplywu perazyny, flufenazyny, trifluoroperazyny, chloropromazny i haloperydolu na objawy pierwotne i deficytowe pierwszego zachorowania na schizofrenie paranoidalna]. Psychiatria Polska1989;23(1):24‐30. ">Terminska 1989</a>; <a href="./references#CD009396-bbs2-0031" title="VinarO , TaussigovaD . Clinical experience with trifluoperazine. Activitas Nervosa Superior1968;8:447‐51. ">Vinar 1968</a>). </p> <p>Altogether 14 studies were excluded because of inappropriate interventions for this review. Of these, three compared trifluoperazine against placebo (<a href="./references#CD009396-bbs2-0011" title="CraneGE . High doses of trifluperazine and tardive dyskinesia. Archives of Neurology1970;22(2):176‐80. ">Crane 1970</a>; <a href="./references#CD009396-bbs2-0019" title="HershonHI , KennedyPF , McGuireRJ . Persistence of extra‐pyramidal disorders and psychiatric relapse after withdrawal of long‐term phenothiazine therapy. British Journal of Psychiatry1972;120(554):41‐50. ">Hershon 1972</a>; <a href="./references#CD009396-bbs2-0033" title='WestonFK , LoftusAP . A terminal double‐blind trial of tri‐fluoperazine ("stelazine") in chronic schizophrenia. Medical Journal of Australia1961;48(1):776‐80. '>Weston 1961</a>), five examined combination treatment (<a href="./references#CD009396-bbs2-0009" title="CaseyJF , HollisterLE , KlettCJ , LaskyJJ , CaffeyEM . Combined drug therapy of chronic schizophrenics. Controlled evaluation of placebo, dextro‐amphetamine, imipramine, isocarboxazid and trifluoperazine added to maintenance doses of chlorpromazine. American Journal of Psychiatry1961;117:997‐1003. ">Casey 1961</a>; <a href="./references#CD009396-bbs2-0013" title="DeWolfeAS , BarrellRP , LondonL , SpanerFE . Prolixin enanthate and thorazine‐stelazine regimens in the treatment of schizophrenic patients. An experimental evaluation. Psychosomatics1971;12(3):186‐90. ">DeWolfe 1971</a>; <a href="./references#CD009396-bbs2-0024" title="PrienRF , LevineJ , ColeJO . High dose trifluoperazine therapy in chronic schizophrenia. American Journal of Psychiatry1969;126(3):305‐13. ">Prien 1969</a>; <a href="./references#CD009396-bbs2-0026" title="SmithJA , ChristianD , RutherfordA , MansfieldE . A comparison of triflupromazine (vesprin), chlorpromazine and PLACEBO in 85 chronic patients. American Journal of Psychiatry1958;115:253‐4. ">Smith 1958</a>; <a href="./references#CD009396-bbs2-0034" title="WilsonIC , McKayJ , SandiferMG . A double‐blind trial to investigate the effects of thorazine (largactil, chlorpromazine), compazine (stemetil, prochlorperazine) and stelazine (trifluoperazine) in paranoid schizophrenia. Journal of Mental Science1961;107:90‐9. ">Wilson 1961</a>), <a href="./references#CD009396-bbs2-0018" title="HamiltonM , HordernA , WaldropFN , LofftJ . A controlled trial on the value of prochlorperazine, trifluoperazine and intensive group treatment. British Journal of Psychiatry1963;109:510‐22. ">Hamilton 1963</a> and <a href="./references#CD009396-bbs2-0016" title="GardosG , FinnertyRJ , ColeJO . Thiothixene and trifluoperazine in a step system. Psychosomatics1970;11(1):36‐40. ">Gardos 1970</a> compared trifluoperazine with mid‐potency antipsychotics, two studies compared trifluoperazine with another high‐potency antipsychotic (triperidol) (<a href="./references#CD009396-bbs2-0021" title="MarjerrisonG , HrychukW , VarsanyiEI . A comparison of two butyrophenones with trifluoperazine. Canadian Psychiatric Association Journal1966;11(1):26‐30. ">Marjerrison 1966</a>; <a href="./references#CD009396-bbs2-0023" title="PrienRF , LevineJ , ColeJO . High dose therapy in chronic schizophrenia ‐ trifuoperazine. Proceedings of the 121st Annual Meeting of the American Psychiatric Association; 1968 May 13‐17; Boston, Massachusetts, USA. 1968. ">Prien 1968</a>) and one study compared trifluoperazine with other phenothiazine derivatives, but did not report exactly which ones (<a href="./references#CD009396-bbs2-0025" title="RudyL , RinaldiE , HimwichH , TuteurW , GlotzerJ . Trifluoperazine in the treatment of psychotic patients. American Journal of Psychiatry1958;115:364‐5. ">Rudy 1958</a>). One study did not include trifluoperazine (<a href="./references#CD009396-bbs2-0032" title="WelbelL . Differences in the clinical effect of various neuroleptics [Roznice w dziallaniu klinicznym niektorych neuroleptykow]. Psychiatria Polska1980;14(2):113‐8. ">Welbel 1980</a>). Seven studies were excluded because they did not present any usable data for this review (<a href="./references#CD009396-bbs2-0012" title="deJongJ . Efficacy of phenothiazines without antiparkinson drugs. Diseases of the Nervous System1965;26(11):702‐4. ">de Jong 1965</a>; <a href="./references#CD009396-bbs2-0014" title="EitanN , LevinY , Ben ArtziE , LevyA , NeumannM . Effects of antipsychotic drugs on memory functions of schizophrenic patients. Acta Psychiatrica Scandinavica1992;85(1):74‐6. ">Eitan 1992</a>; <a href="./references#CD009396-bbs2-0020" title="JonesIH , PiklerN . Effects of chlorpromazine and trifluoperazine on the activity of chronic schizophrenics. British Journal of Psychiatry1971;119(552):545‐6. ">Jones 1971</a>; <a href="./references#CD009396-bbs2-0022" title="PlatzAR , KlettCJ , CaffeyEM . Selective drug action related to chronic schizophrenic subtype (A comparative study of carphenazine, chlorpromazine, and trifluoperazine). Diseases of the Nervous System1967;28(9):601‐5. ">Platz 1967</a>; <a href="./references#CD009396-bbs2-0027" title="SpiegelDE , Keith‐SpiegelP . The effects of carphenazine, trifluoperazine and chlorpromazine on ward behavior, physiological functioning and psychological test scores in chronic schizophrenic patients. Journal of Nervous and Mental Diseases1967;144(2):111‐6. ">Spiegel 1967</a>; <a href="./references#CD009396-bbs2-0028" title="TejaJS , GreyWH , ClumJM , WarrenC . Tranquilizers or anti‐depressants for chronic schizophrenics: a long term study. Australian and New Zealand Journal of Psychiatry1975;9(4):241‐7. ">Teja 1975</a>; <a href="./references#CD009396-bbs2-0030" title="VestreND , SchieleBC . Differential drug effects of two phenothiazines (A controlled comparison of thioridazine and trifluoperazine in chronic schizophrenics). Diseases of the Nervous System1970;31(12):821‐5. ">Vestre 1970</a>). </p> </section> </section> <section id="CD009396-sec-0118"> <h3 class="title">Risk of bias in included studies</h3> <p>For graphical representations of our judgements of risk of bias please refer to <a href="#CD009396-fig-0002">Figure 2</a> and <a href="#CD009396-fig-0003">Figure 3</a>. Full details of judgements are presented in the 'Risk of bias' tables. </p> <div class="figure" id="CD009396-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD009396-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/image_n/nCD009396-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD009396-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009396-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/image_n/nCD009396-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD009396-sec-0119"> <h4 class="title">Allocation</h4> <p>All studies were judged with an unclear risk of bias concerning random sequence generation, because all were described as randomised but none gave further information on sequence generation. </p> <p>Two studies were rated with low risk of bias on allocation concealment; both reported that the only ones with access to the identity of patients were the unit secretary (<a href="./references#CD009396-bbs2-0004" title="LeffJP , HirschSR , GaindR , RohdePD , StevensBC . Life events and maintenance therapy in schizophrenic relapse. British Journal of Psychiatry1973;123:659‐60. LeffJP , WingJK . Trial of maintenance therapy in schizophrenia. British Medical Journal1971;3:599‐604. ">Leff 1971</a>) or the hospital pharmacist (<a href="./references#CD009396-bbs2-0005" title="MortonMR . A study of the withdrawal of chlorpromazine or trifluoperazine in chronic schizophrenia. American Journal of Psychiatry1968;124(11):1585‐8. ">Morton 1968</a>). Five of the included randomised studies did not provide details on allocation concealment and were thus rated as 'unclear'. </p> </section> <section id="CD009396-sec-0120"> <h4 class="title">Blinding</h4> <p>Four studies were double‐blind and provided at least some details about the process (usually identical capsules) so that they were rated as low risk of bias in terms of blinding (<a href="./references#CD009396-bbs2-0001" title="CoonsWH , BoydBA , WhiteJG . Chlorpromazine, trifluoperazine and placebo with long‐term mental hospital patients. Canadian Psychiatric Association Journal1962;7(4):159‐63. ">Coons 1962</a>; <a href="./references#CD009396-bbs2-0003" title="HollisterLE , EricksonGV , MotzenteckerFP . Trifluoperazine in chronic psychiatric patients. Journal of Clinical and Experimental Psychopathology 19610;21:15‐23. ">Hollister 1960</a>; <a href="./references#CD009396-bbs2-0004" title="LeffJP , HirschSR , GaindR , RohdePD , StevensBC . Life events and maintenance therapy in schizophrenic relapse. British Journal of Psychiatry1973;123:659‐60. LeffJP , WingJK . Trial of maintenance therapy in schizophrenia. British Medical Journal1971;3:599‐604. ">Leff 1971</a>; <a href="./references#CD009396-bbs2-0007" title="SchieleBC , VestreND , SteinKE . A comparison of thioridazine, trifluoperazine, chlorpromazine, and placebo: a double‐blind controlled study on the treatment of chronic hospitalized, schizophrenic patients. Journal of Clinical and Experimental Psychopathology1961;22:151‐62. ">Schiele 1961</a>). In <a href="./references#CD009396-bbs2-0002" title="HanlonTE , MichauxMH , OtaKY , ShafferJW , KurlandAA . The comparative effectiveness of eight phenthiazines. Psychopharmacologia1965;7:89‐106. ">Hanlon 1965</a> there could have been a performance bias, because treating ward physicians were aware of the various drugs and dosages involved in the study. <a href="./references#CD009396-bbs2-0005" title="MortonMR . A study of the withdrawal of chlorpromazine or trifluoperazine in chronic schizophrenia. American Journal of Psychiatry1968;124(11):1585‐8. ">Morton 1968</a> was a double‐blind study, but the nurses correctly guessed the drugs participants were assigned to. Thus blinding did not work in this study. <a href="./references#CD009396-bbs2-0006" title="ReardonJD , AbramsS . Acute paranoid schizophrenia (treatment with chlorpromazine, trifluoperazine and placebo). Diseases of the Nervous System1966;27:265‐70. ">Reardon 1966</a> just stated that “neither the ward personnel nor the investigators knew which drug the patients received”, but there was no detail about the blinding methods. We classified the study as 'unclear' risk in terms of blinding. </p> </section> <section id="CD009396-sec-0121"> <h4 class="title">Incomplete outcome data</h4> <p>One study was judged to have a low risk of bias (<a href="./references#CD009396-bbs2-0007" title="SchieleBC , VestreND , SteinKE . A comparison of thioridazine, trifluoperazine, chlorpromazine, and placebo: a double‐blind controlled study on the treatment of chronic hospitalized, schizophrenic patients. Journal of Clinical and Experimental Psychopathology1961;22:151‐62. ">Schiele 1961</a>). Four studies were judged unclear in terms of incomplete outcome data. Of these, <a href="./references#CD009396-bbs2-0003" title="HollisterLE , EricksonGV , MotzenteckerFP . Trifluoperazine in chronic psychiatric patients. Journal of Clinical and Experimental Psychopathology 19610;21:15‐23. ">Hollister 1960</a> and <a href="./references#CD009396-bbs2-0005" title="MortonMR . A study of the withdrawal of chlorpromazine or trifluoperazine in chronic schizophrenia. American Journal of Psychiatry1968;124(11):1585‐8. ">Morton 1968</a> did not address whether there were drop‐outs. <a href="./references#CD009396-bbs2-0004" title="LeffJP , HirschSR , GaindR , RohdePD , StevensBC . Life events and maintenance therapy in schizophrenic relapse. British Journal of Psychiatry1973;123:659‐60. LeffJP , WingJK . Trial of maintenance therapy in schizophrenia. British Medical Journal1971;3:599‐604. ">Leff 1971</a> did not report drop‐outs separately for each drug group.<br/> <br/> We judged two studies to have a high risk of incomplete outcome data; <a href="./references#CD009396-bbs2-0002" title="HanlonTE , MichauxMH , OtaKY , ShafferJW , KurlandAA . The comparative effectiveness of eight phenthiazines. Psychopharmacologia1965;7:89‐106. ">Hanlon 1965</a> and <a href="./references#CD009396-bbs2-0006" title="ReardonJD , AbramsS . Acute paranoid schizophrenia (treatment with chlorpromazine, trifluoperazine and placebo). Diseases of the Nervous System1966;27:265‐70. ">Reardon 1966</a> had an attrition rate of more than 20% and included only study completers in the final analysis. </p> </section> <section id="CD009396-sec-0122"> <h4 class="title">Selective reporting</h4> <p>We judged two studies to be free of selective reporting (<a href="./references#CD009396-bbs2-0003" title="HollisterLE , EricksonGV , MotzenteckerFP . Trifluoperazine in chronic psychiatric patients. Journal of Clinical and Experimental Psychopathology 19610;21:15‐23. ">Hollister 1960</a>; <a href="./references#CD009396-bbs2-0005" title="MortonMR . A study of the withdrawal of chlorpromazine or trifluoperazine in chronic schizophrenia. American Journal of Psychiatry1968;124(11):1585‐8. ">Morton 1968</a>). One study was rated with an unclear risk of selective reporting (<a href="./references#CD009396-bbs2-0001" title="CoonsWH , BoydBA , WhiteJG . Chlorpromazine, trifluoperazine and placebo with long‐term mental hospital patients. Canadian Psychiatric Association Journal1962;7(4):159‐63. ">Coons 1962</a>). Four studies were rated with a high risk of bias. Of these, the following three studies did not (sufficiently) report on important outcomes: <a href="./references#CD009396-bbs2-0002" title="HanlonTE , MichauxMH , OtaKY , ShafferJW , KurlandAA . The comparative effectiveness of eight phenthiazines. Psychopharmacologia1965;7:89‐106. ">Hanlon 1965</a>, <a href="./references#CD009396-bbs2-0006" title="ReardonJD , AbramsS . Acute paranoid schizophrenia (treatment with chlorpromazine, trifluoperazine and placebo). Diseases of the Nervous System1966;27:265‐70. ">Reardon 1966</a>, <a href="./references#CD009396-bbs2-0007" title="SchieleBC , VestreND , SteinKE . A comparison of thioridazine, trifluoperazine, chlorpromazine, and placebo: a double‐blind controlled study on the treatment of chronic hospitalized, schizophrenic patients. Journal of Clinical and Experimental Psychopathology1961;22:151‐62. ">Schiele 1961</a>. <a href="./references#CD009396-bbs2-0004" title="LeffJP , HirschSR , GaindR , RohdePD , StevensBC . Life events and maintenance therapy in schizophrenic relapse. British Journal of Psychiatry1973;123:659‐60. LeffJP , WingJK . Trial of maintenance therapy in schizophrenia. British Medical Journal1971;3:599‐604. ">Leff 1971</a> did not report results separately for the drug groups. </p> </section> <section id="CD009396-sec-0123"> <h4 class="title">Other potential sources of bias</h4> <p>We judged four studies to be free of other bias (<a href="./references#CD009396-bbs2-0003" title="HollisterLE , EricksonGV , MotzenteckerFP . Trifluoperazine in chronic psychiatric patients. Journal of Clinical and Experimental Psychopathology 19610;21:15‐23. ">Hollister 1960</a>; <a href="./references#CD009396-bbs2-0004" title="LeffJP , HirschSR , GaindR , RohdePD , StevensBC . Life events and maintenance therapy in schizophrenic relapse. British Journal of Psychiatry1973;123:659‐60. LeffJP , WingJK . Trial of maintenance therapy in schizophrenia. British Medical Journal1971;3:599‐604. ">Leff 1971</a>, <a href="./references#CD009396-bbs2-0006" title="ReardonJD , AbramsS . Acute paranoid schizophrenia (treatment with chlorpromazine, trifluoperazine and placebo). Diseases of the Nervous System1966;27:265‐70. ">Reardon 1966</a>; <a href="./references#CD009396-bbs2-0007" title="SchieleBC , VestreND , SteinKE . A comparison of thioridazine, trifluoperazine, chlorpromazine, and placebo: a double‐blind controlled study on the treatment of chronic hospitalized, schizophrenic patients. Journal of Clinical and Experimental Psychopathology1961;22:151‐62. ">Schiele 1961</a>) and in the remaining three studies this was unclear. </p> </section> </section> <section id="CD009396-sec-0124"> <h3 class="title" id="CD009396-sec-0124">Effects of interventions</h3> <p>See: <a href="./full#CD009396-tbl-0001"><b>Summary of findings for the main comparison</b> Trifluoperazine versus low‐potency antipsychotic drugs for schizophrenia</a> </p> <p>For dichotomous data, we calculated risk ratios (RR) with 95% confidence intervals (CI). </p> <section id="CD009396-sec-0125"> <h4 class="title">1. Trifluoperazine versus low‐potency antipsychotic drugs</h4> <section id="CD009396-sec-0126"> <h5 class="title">1.1 Response to treatment</h5> <p>There was no difference in response to treatment as defined by the original studies in three medium‐term studies (trifluoperazine 30%, low‐potency drug 36%, 3 RCTs, n = 120, RR 0.96, CI 0.59 to 1.56). </p> </section> <section id="CD009396-sec-0127"> <h5 class="title">1.2 Leaving the study early</h5> <section id="CD009396-sec-0128"> <h6 class="title">1.2.1 Acceptability of treatment ‐ Leaving the study early due to any reason</h6> <p>There was no significant difference between trifluoperazine and low‐potency antipsychotics, neither in the short term (trifluoperazine 25%, low‐potency antipsychotics 21%, 2 RCTs, n = 179, RR 1.23, CI 0.70 to 2.15), nor in the medium term (trifluoperazine 5%, low‐potency antipsychotics 3%, 1 RCT, n = 60, RR 2.00, CI 0.13 to 30.34), and also not overall (trifluoperazine 20%, low‐potency antipsychotics 16%, 3 RCTs, n = 239, RR 1.25, CI 0.72 to 2.17). </p> </section> <section id="CD009396-sec-0129"> <h6 class="title">1.2.2 Leaving the study early due to adverse events</h6> <p>There was no significant difference between trifluoperazine and low‐potency antipsychotics, neither in the short term (trifluoperazine 8%, low‐potency antipsychotics 6%, 2 RCTs, n = 179, RR 1.44. CI 0.48 to 4.33), nor in the medium term (trifluoperazine 0%, low‐potency antipsychotics 0%, 1 RCT, n = 60, RR not estimable), and also not overall (trifluoperazine 6%, low‐potency antipsychotics 4%, 3 RCTs, n = 239, RR 1.44, CI 0.48 to 4.33). </p> </section> <section id="CD009396-sec-0130"> <h6 class="title">1.2.3 Leaving the study early due to inefficacy of treatment</h6> <p>There was no significant difference between trifluoperazine and low‐potency antipsychotics, neither in the short term (trifluoperazine 3%, low‐potency antipsychotics 1%, 2 RCTs, n = 179, RR 2.00, CI 0.21 to 18.98), nor in the medium term (trifluoperazine 0%, low‐potency antipsychotics 3%, 1 RCT, n = 60, RR 0.65, CI 0.03 to 15.30), and also not overall (trifluoperazine 2%, low‐potency antipsychotics 1%, 3 RCTs, n = 239, RR 1.37, CI 0.22 to 8.56). </p> </section> </section> <section id="CD009396-sec-0131"> <h5 class="title">1.3 Relapse</h5> <p>There was no significant difference between trifluoperazine and low‐potency antipsychotics, neither in the short term (trifluoperazine 9%, low‐potency antipsychotics 9%, 1 RCT, n = 22, RR 1.00, CI 0.07 to 14.05), nor in the medium term (trifluoperazine 15%, low‐potency antipsychotics 6%, 3 RCTs, n = 120, RR 1.64, CI 0.52 to 5.16), and also not in the long term (trifluoperazine 38%, low‐potency antipsychotics 20%, 1 RCT, n = 18, RR 1.92, CI 0.29 to 12.64). The overall results also did not show a significant difference (trifluoperazine 18%, low‐potency antipsychotics 7%, 5 RCTs, n = 160, RR 1.60, CI 0.64 to 4.02). </p> </section> <section id="CD009396-sec-0132"> <h5 class="title">1.4 Adverse effects</h5> <section id="CD009396-sec-0133"> <h6 class="title">1.4.1 General ‐ At least one adverse effect</h6> <p>There was no significant difference (trifluoperazine 60%, low‐potency antipsychotics 38%, 1 RCT, n = 60, RR 1.60, CI 0.94 to 2.74). </p> </section> <section id="CD009396-sec-0134"> <h6 class="title">1.4.2 Specific ‐ Movement disorders</h6> <p>There was a significant difference in terms of at least one movement disorder in favour of low‐potency antipsychotics (trifluoperazine 23%, low‐potency antipsychotics 13%, 2 RCTs, n = 123, RR 2.08, CI 0.78 to 5.55). </p> <section id="CD009396-sec-0135"> <p><b>a. Akathisia</b></p> <p>There was no significant difference (trifluoperazine 6%, low‐potency antipsychotics 1%, 1 RCT, n = 157, RR 6.06, CI 0.65 to 56.82). </p> </section> <section id="CD009396-sec-0136"> <p><b>b. Akinesia</b></p> <p>There was no significant difference (trifluoperazine 2%, low‐potency antipsychotics 1%, 1 RCT, n = 157, RR 2.02, CI 0.13 to 31.64). </p> </section> <section id="CD009396-sec-0137"> <p><b>c. Dyskinesia</b></p> <p>There was no significant difference (trifluoperazine 4%, low‐potency antipsychotics 1%, 1 RCT, n = 157, RR 4.04, CI 0.37 to 43.52). </p> </section> <section id="CD009396-sec-0138"> <p><b>d. Incoordination</b></p> <p>There was a significant difference in favour of low‐potency antipsychotics (trifluoperazine 20%, low‐potency antipsychotics 5%, 1 RCT, n = 60, RR 7.00, CI 1.60 to 30.66). </p> </section> <section id="CD009396-sec-0139"> <p><b>e. Rigor</b></p> <p>There was a significant difference in favour of low‐potency antipsychotics (trifluoperazine 45%, low‐potency antipsychotics 10%, 1 RCT, n = 60, RR 4.50, CI 1.58 to 12.84). </p> </section> </section> <section id="CD009396-sec-0140"> <h6 class="title">1.4.3 Other</h6> <section id="CD009396-sec-0141"> <p><b>a. Anticholinergic</b></p> <p>There was no significant difference for blurring of vision (trifluoperazine 5%, low‐potency antipsychotics 0%, 1 RCT, n = 60, RR 9.76, CI 0.49 to 194.21) or drooling (trifluoperazine 10%, low‐potency antipsychotics 3%, 1 RCT, n = 60, RR 4.00, CI 0.39 to 41.51). </p> </section> <section id="CD009396-sec-0142"> <p><b>b. Cardiovascular</b></p> <p>There was no significant difference for dizziness (trifluoperazine 0%, low‐potency antipsychotics 1%, 1 RCT, n = 157, RR 0.67, CI 0.03 to 16.09) or syncope (trifluoperazine 0%, low‐potency antipsychotics 3%, 1 RCT, n = 60, RR 0.65, CI 0.03 to 15.30). </p> </section> <section id="CD009396-sec-0143"> <p><b>c. Central nervous system</b></p> <p>There was no significant difference for a whole series of adverse effects of central nervous system origin including drowsiness (trifluoperazine 20%, low‐potency antipsychotics 23%, 1 RCT, n = 60, RR 0.89, CI 0.31 to 2.54), insomnia (trifluoperazine 0%, low‐potency antipsychotics 0%, 1 RCT, n = 60, RR not estimable), lethargy (trifluoperazine 5%, low‐potency antipsychotics 0%, 1 RCT, n = 60, RR 5.86, CI 0.25 to 137.66), muscle weakness (trifluoperazine 10%, low‐potency antipsychotics 3%, 1 RCT, n = 60, RR 4.00, CI 0.39 to 41.51), seizure (trifluoperazine 0%, low‐potency antipsychotics 0%, 1 RCT, n = 60, RR not estimable), tenseness (trifluoperazine 0%, low‐potency antipsychotics 3%, 1 RCT, n = 60, RR 0.65, CI 0.03 to 15.30) and slurred speech (trifluoperazine 5%, low‐potency antipsychotics 3%, 1 RCT, n = 60, RR 2.00, CI 0.13 to 30.34). </p> </section> <section id="CD009396-sec-0144"> <p><b>d. Dermatological</b></p> <p>There was no significant difference for the outcome of skin disorder (trifluoperazine 4%, low‐potency antipsychotics 5%, 2 RCTs, n = 217, RR 0.99, CI 0.28 to 3.50). </p> </section> <section id="CD009396-sec-0145"> <p><b>e. Gastrointestinal</b></p> <p>There was no significant difference for the outcome of decreased appetite (trifluoperazine 0%, low‐potency antipsychotics 0%, 1 RCT, n = 60, RR not estimable). </p> </section> <section id="CD009396-sec-0146"> <p><b>f. Metabolic</b></p> <p>There was no significant difference for polydipsia and polyuria (trifluoperazine 0%, low‐potency antipsychotics 0%, 1 RCT, n = 60, RR not estimable). </p> </section> </section> </section> <section id="CD009396-sec-0147"> <h5 class="title">1.5 Missing outcomes</h5> <p>There were no data on important side‐effects such as hypotension, and sedation, and no data on service use, death and quality of life. </p> </section> </section> <section id="CD009396-sec-0148"> <h4 class="title">2. Subgroup analyses</h4> <p>All subgroup analyses were conducted only on the primary outcome response to treatment as defined by the original studies. </p> <section id="CD009396-sec-0149"> <h5 class="title">2.1 Different low‐potency drugs</h5> <p>Three studies compared trifluoperazine with chlorpromazine and there was no significant difference (trifluoperazine 30%, low‐potency drug 33%, 3 RCTs, n = 100, RR 1.05, CI 0.54 to 2.06). The comparison with thioridazine (trifluoperazine 30%, thioridazine 45%, 1 RCT, n = 40, RR 0.89, CI 0.43 to 1.83) also did not lead to a significant difference. </p> </section> <section id="CD009396-sec-0150"> <h5 class="title">2.2 Clinical state, stage or problem</h5> <p>All three studies with data on response to treatment included participants with chronic schizophrenia. Therefore, this subgroup comparison did not apply.<br/> <br/> One study included participants who were treatment resistant and did not show a superiority of trifluoperazine compared with low‐potency antipsychotics (drug 30%, low‐potency antipsychotics 35%, 1 RCT, n = 60, RR 1.14, CI 0.58 to 2.26). There was no significant difference compared to the rest of the studies (test for subgroup differences: Chi² = 0.52, df = 1 (P = 0.47), I² = 0%). </p> </section> </section> <section id="CD009396-sec-0151"> <h4 class="title">3. Sensitivity analyses</h4> <p>All sensitivity analyses were conducted only on the primary outcome response to treatment as defined by the original studies. </p> <section id="CD009396-sec-0152"> <h5 class="title">3.1 Exclusion of studies that were judged to be at high risk of bias</h5> <p>There were no studies with data on the primary outcome that were judged to be at high risk of bias. </p> </section> <section id="CD009396-sec-0153"> <h5 class="title">3.2 Assessment of dosage</h5> <p>There were no clearly discrepant doses between trifluoperazine and low‐potency antipsychotics.</p> </section> <section id="CD009396-sec-0154"> <h5 class="title">3.3 Imputed values</h5> <p>This sensitivity analysis did not apply.</p> </section> <section id="CD009396-sec-0155"> <h5 class="title">3.4 Fixed‐effect model</h5> <p>When a fixed‐effect model was applied, the efficacy of trifluoperazine was also not different from that of low‐potency drugs (trifluoperazine 26%, low‐potency drug 27%, 2 RCTs, n = 60, RR 0.08 CI 0.40 to 1.60). </p> </section> <section id="CD009396-sec-0156"> <h5 class="title">3.5 Investigation of heterogeneity</h5> <p>There was no heterogeneity for the primary outcome response to treatment (P = 0.61, I<sup>2</sup> = 0%). </p> </section> </section> <section id="CD009396-sec-0157"> <h4 class="title">4. Other results</h4> <section id="CD009396-sec-0158"> <h5 class="title">4.1 Publication bias</h5> <p>Only three studies reported results on the primary outcome response to treatment, therefore we did not use funnel plots. </p> </section> <section id="CD009396-sec-0159"> <h5 class="title">4.2 'Summary of findings' table</h5> <p>The results of the outcomes response to treatment, leaving the study early, at least one adverse event, at least one movement disorder, sedation, death and quality of life were inspected more closely (see <a href="./full#CD009396-tbl-0001">summary of findings Table for the main comparison</a>). Based on this tool, we considered the quality of the results for the outcomes response to treatment and at least one adverse event to be moderate, for leaving the study due to any reason to be low and at least one adverse event to be very low. Moreover, no data on the predefined outcomes death, sedation and quality of life were available. The judgements derived from this instrument were used for the discussion section of the review (see <a href="#CD009396-sec-0160">Discussion</a> ‐ <a href="#CD009396-sec-0161">Summary of main results</a>). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD009396-sec-0160" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD009396-sec-0160"></div> <section id="CD009396-sec-0161"> <h3 class="title" id="CD009396-sec-0161">Summary of main results</h3> <section id="CD009396-sec-0162"> <h4 class="title">1. General</h4> <p>Conventional antipsychotic drugs are still used in the treatment of schizophrenia, both in poorer as well as in richer countries. This review compared trifluoperazine with low‐potency conventional antipsychotics, including seven studies with 422 participants. No significant difference between trifluoperazine and low‐potency antipsychotics was found in the primary outcome response to treatment. This finding is in line with the statements of treatment guidelines that low‐potency drugs are as efficacious as high‐potency antipsychotics such as trifluoperazine and contrasts with a clinical impression that low‐potency conventional antipsychotic drugs are less efficacious. However, there are limitations to this review. Only three studies reported data on the primary outcome. Approximately 1000 participants need to be included in psychiatric meta‐analyses for the results to be robust (<a href="./references#CD009396-bbs2-0078" title="TrikalinosTA , ChurchillR , FerriM , LeuchtS , TuunainenA , WahlbeckK , et al. EU‐PSI project. Effect sizes in cumulative meta‐analyses of mental health randomized trials evolved over time. Journal of Clinical Epidemiology2004;57(11):1124‐30. ">Trikalinos 2004</a>). However, the current systematic review included much fewer participants, the primary outcome response to treatment was based on 120 participants, thus it was underpowered. Also, for studies conducted in the 1960s and 1970s operationalised diagnostic criteria such as DSM‐III or its more recent versions were not available. The studies inconsistently addressed and reported the primary outcome clinical response and the methods of sequence generation and blinding were often poorly reported. Other outcomes such as hospital admission, quality of life and employment, which are clinically relevant have not been reported at all. In summary, the included studies do not allow us to make sound conclusions about the relative tolerability and efficacy of trifluoperazine compared with low‐potency antipsychotics. This is also supported by a judgement of low to moderate quality for outcomes in the <a href="./full#CD009396-tbl-0001">summary of findings Table for the main comparison</a>. </p> </section> <section id="CD009396-sec-0163"> <h4 class="title">2. Treatment effects</h4> <section id="CD009396-sec-0164"> <h5 class="title">2.1 Response to treatment</h5> <p>The overall results of response to treatment do not suggest a difference in efficacy between trifluoperazine and low‐potency antipsychotic drugs. This result supports early narrative work, which was not based on meta‐analytic methods (<a href="./references#CD009396-bbs2-0043" title="DavisJM , BarterJT , KaneJM . Antipsychotic drugs. Comprehensive Textbook of Psychiatry. Williams and Wilkins, 1989. ">Davis 1989</a>; <a href="./references#CD009396-bbs2-0059" title="KleinDF , DavisJM . Diagnosis and Drug Treatment of Psychiatric Disorders. Baltimore: Williams and Wilkins, 1969. ">Klein 1969</a>), and does not confirm a clinical perception that low‐potency antipsychotic drugs are less efficacious than trifluoperazine. Due to the fact that only three studies reported on this outcome and that the number of participants was small ‐ altogether 120 participants ‐ this result is inconclusive. Also, the criteria and cut‐offs used for the primary outcome “response to treatment” varied, although a study showed that this is not so much of a problem as long as relative risks and odds ratios are used (<a href="./references#CD009396-bbs2-0050" title="FurukawaTA , AkechiT , WagenpfeilS , LeuchtS . Relative indices of treatment effect may be constant across different definitions of response in schizophrenia trials. Schizophrenia Research2011;126:212‐9. ">Furukawa 2011</a>) . </p> </section> <section id="CD009396-sec-0165"> <h5 class="title">2.2 Leaving the study early</h5> <p>There was no significant difference between trifluoperazine and low‐potency antipsychotics for leaving the study early due to any reason; it seems that both trifluoperazine and low‐potency antipsychotics are not different in their overall acceptability for participants with schizophrenia. We also found no significant difference for leaving the study early due to adverse events or inefficacy. However, only three studies reported data on this outcome, which is very little and more data would be needed for a clear interpretation here. </p> </section> <section id="CD009396-sec-0166"> <h5 class="title">2.3 Adverse effects</h5> <p>For those studies that reported on adverse events, trifluoperazine produced more movement disorders in terms of at least one movement disorder, incoordination and rigor. The findings on extrapyramidal side‐effects are in line with today's knowledge that high‐potency and low‐potency antipsychotics have different affinities and binding properties to dopamine and thus differ in the types of adverse events, such as movement disorders. However, data on other important adverse events such as weight gain and sedation were not reported at all, so differences in affinities to other receptors such as histamine receptors could not be confirmed. </p> </section> <section id="CD009396-sec-0167"> <h5 class="title">2.4 Other predefined outcomes</h5> <p>None of the included studies reported on cardiac effects, hypotension, sedation, weight gain, service use and death. Data on quality of life, participant´s/carer´s satisfaction with care or economic outcomes were also not reported. These outcomes may be more important for policy makers than conventional measures of efficacy and tolerability. It is therefore disappointing that they are not available. </p> </section> </section> <section id="CD009396-sec-0168"> <h4 class="title">3. Publication bias</h4> <p>Due to the limited number of studies that reported on the primary outcome, the test for funnel plot asymmetry was not meaningful. </p> </section> <section id="CD009396-sec-0169"> <h4 class="title">4. Subgroup analyses and investigation of heterogeneity</h4> <p>The effects of trifluoperazine versus each single low‐potency antipsychotic drug did not show any significant difference, but the results were clearly limited by the small number of trials assigned to each single low‐potency drug. There was also no difference in effect between studies with treatment resistant participants and the remaining studies. Other subgroup analyses such as studies with diagnoses other than schizophrenia or first episode were not applicable for the three studies which provided data on the primary outcome response to treatment. </p> </section> <section id="CD009396-sec-0170"> <h4 class="title">5. Sensitivity analyses</h4> <p>The results of the primary outcome were not different when a fixed‐effects model instead of a random‐effects model was applied. The other predefined sensitivity analyses on risk of bias, dose and imputed values, did not apply to the three studies that reported on the primary outcome. </p> </section> </section> <section id="CD009396-sec-0171"> <h3 class="title" id="CD009396-sec-0171">Overall completeness and applicability of evidence</h3> <p>Most of the included studies were conducted in hospitals and in different countries. Two studies were from the 1970s and all the other studies from the 1960s. Almost all diagnosed participants according to clinical diagnosis as operationalised diagnostic criteria such as DSM‐III or its more recent versions were not available. Thus it is possible that those older studies included participants who nowadays might sometimes have another diagnosis than schizophrenia. Overall, seven of the included studies either did not report on the primary outcome or did not report results independently of the treatment condition. Thus, these included studies could not be used for the main outcome. The evidence on adverse events is particularly incomplete, as none of the included studies reported on important adverse events such as death, suicide, cardiac effects, sedation or weight gain. The comparisons for the primary outcome only included chlorpromazine and one small group that received thioridazine. There were no data on other low‐potency antipsychotics such as mesoridazine, levomepromazine, promazine or perazine, so that the overall evidence on the effectiveness of trifluoperazine compared with low‐potency antipsychotics is incomplete.<br/> <br/> New studies with better outcome reporting would be needed in order to make stronger statements about the differences between trifluoperazine and low‐potency antipsychotic medication for routine care. </p> </section> <section id="CD009396-sec-0172"> <h3 class="title" id="CD009396-sec-0172">Quality of the evidence</h3> <p>Almost all studies were randomised and double‐blind but most of them did not describe exact sequence generation, allocation concealment or detailed blinding methods. Lack of blinding is not necessarily a problem for objective outcomes, but problematic for subjective outcomes such as response to treatment or side‐effects. None of the studies were judged to be free of selective reporting, most of them failed to report on previously defined outcomes or did not report the number of participants randomised to each drug group. Most studies did not address the problem of incomplete outcome data, and this might also have influenced the estimates of effect. Therefore, the overall quality of the included studies was low (see <a href="./full#CD009396-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> <section id="CD009396-sec-0173"> <h3 class="title" id="CD009396-sec-0173">Potential biases in the review process</h3> <p>We pooled all low‐potency antipsychotics in one group for all outcomes except for the primary outcome response to treatment, for which we also performed subgroup analyses on trifluoperazine versus each single low‐potency antipsychotic drug. As there were altogether only two different low‐potency antipsychotics and as both of them were from the phenothiazine class, we felt that pooling the results of these antipsychotics was appropriate. Moreover, the search was based on Cochrane Schizophrenia Trials Register and the last search date was 2010, so it is possible that there are unpublished trials that we are not aware of. There is always a possibility of publication bias, but due to the small number of trials this could not be addressed by funnel‐plots. The initiatives to make all studies available to the public are relatively recent, while most studies were old making publication bias likely. </p> <p>We decided post‐hoc to include all outcomes reported by a study, not only the predefined outcomes. This change to the protocol was made on the basis that other outcomes (e.g. non‐pre‐specified adverse effects) might be important as well and did not affect review authors´ biases. </p> </section> <section id="CD009396-sec-0174"> <h3 class="title" id="CD009396-sec-0174">Agreements and disagreements with other studies or reviews</h3> <p>We are not aware of other reviews on the efficacy of trifluoperazine versus low‐potency antipsychotic drugs. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD009396-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/urn:x-wiley:14651858:media:CD009396:CD009396-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/image_t/tCD009396-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD009396-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/image_n/nCD009396-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/full#CD009396-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/image_n/nCD009396-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009396-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/urn:x-wiley:14651858:media:CD009396:CD009396-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/image_t/tCD009396-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD009396-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/image_n/nCD009396-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/full#CD009396-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/image_n/nCD009396-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009396-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/urn:x-wiley:14651858:media:CD009396:CD009396-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/image_t/tCD009396-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009396-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/image_n/nCD009396-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/full#CD009396-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/image_n/nCD009396-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009396-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/urn:x-wiley:14651858:media:CD009396:CD009396-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/image_t/tCD009396-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Comparison 1: TRIFLUOPERAZINE versus LOW‐POTENCY ANTIPSYCHOTIC DRUGS, Outcome 1 Response to treatment ‐ medium term." data-id="CD009396-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/image_n/nCD009396-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Comparison 1: TRIFLUOPERAZINE versus LOW‐POTENCY ANTIPSYCHOTIC DRUGS, Outcome 1 Response to treatment ‐ medium term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/references#CD009396-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/image_n/nCD009396-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009396-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/urn:x-wiley:14651858:media:CD009396:CD009396-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/image_t/tCD009396-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Comparison 1: TRIFLUOPERAZINE versus LOW‐POTENCY ANTIPSYCHOTIC DRUGS, Outcome 2 Leaving the study early: 1. Acceptability of treatment ‐ leaving early due to any reason." data-id="CD009396-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/image_n/nCD009396-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Comparison 1: TRIFLUOPERAZINE versus LOW‐POTENCY ANTIPSYCHOTIC DRUGS, Outcome 2 Leaving the study early: 1. Acceptability of treatment ‐ leaving early due to any reason. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/references#CD009396-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/image_n/nCD009396-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009396-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/urn:x-wiley:14651858:media:CD009396:CD009396-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/image_t/tCD009396-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Comparison 1: TRIFLUOPERAZINE versus LOW‐POTENCY ANTIPSYCHOTIC DRUGS, Outcome 3 Leaving the study early: 2. Due to adverse effects." data-id="CD009396-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/image_n/nCD009396-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Comparison 1: TRIFLUOPERAZINE versus LOW‐POTENCY ANTIPSYCHOTIC DRUGS, Outcome 3 Leaving the study early: 2. Due to adverse effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/references#CD009396-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/image_n/nCD009396-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009396-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/urn:x-wiley:14651858:media:CD009396:CD009396-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/image_t/tCD009396-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Comparison 1: TRIFLUOPERAZINE versus LOW‐POTENCY ANTIPSYCHOTIC DRUGS, Outcome 4 Leaving the study early: 3. Due to inefficacy." data-id="CD009396-fig-0007" src="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/image_n/nCD009396-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Comparison 1: TRIFLUOPERAZINE versus LOW‐POTENCY ANTIPSYCHOTIC DRUGS, Outcome 4 Leaving the study early: 3. Due to inefficacy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/references#CD009396-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/image_n/nCD009396-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009396-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/urn:x-wiley:14651858:media:CD009396:CD009396-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/image_t/tCD009396-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Comparison 1: TRIFLUOPERAZINE versus LOW‐POTENCY ANTIPSYCHOTIC DRUGS, Outcome 5 Relapse." data-id="CD009396-fig-0008" src="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/image_n/nCD009396-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Comparison 1: TRIFLUOPERAZINE versus LOW‐POTENCY ANTIPSYCHOTIC DRUGS, Outcome 5 Relapse. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/references#CD009396-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/image_n/nCD009396-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009396-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/urn:x-wiley:14651858:media:CD009396:CD009396-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/image_t/tCD009396-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Comparison 1: TRIFLUOPERAZINE versus LOW‐POTENCY ANTIPSYCHOTIC DRUGS, Outcome 6 Adverse events: 1. General ‐ at least one adverse effect." data-id="CD009396-fig-0009" src="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/image_n/nCD009396-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Comparison 1: TRIFLUOPERAZINE versus LOW‐POTENCY ANTIPSYCHOTIC DRUGS, Outcome 6 Adverse events: 1. General ‐ at least one adverse effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/references#CD009396-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/image_n/nCD009396-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009396-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/urn:x-wiley:14651858:media:CD009396:CD009396-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/image_t/tCD009396-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Comparison 1: TRIFLUOPERAZINE versus LOW‐POTENCY ANTIPSYCHOTIC DRUGS, Outcome 7 Adverse events: 2.a. Specific ‐ movement disorders." data-id="CD009396-fig-0010" src="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/image_n/nCD009396-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Comparison 1: TRIFLUOPERAZINE versus LOW‐POTENCY ANTIPSYCHOTIC DRUGS, Outcome 7 Adverse events: 2.a. Specific ‐ movement disorders. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/references#CD009396-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/image_n/nCD009396-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009396-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/urn:x-wiley:14651858:media:CD009396:CD009396-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/image_t/tCD009396-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Comparison 1: TRIFLUOPERAZINE versus LOW‐POTENCY ANTIPSYCHOTIC DRUGS, Outcome 8 Adverse effects: 2.b. Specific ‐ others." data-id="CD009396-fig-0011" src="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/image_n/nCD009396-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Comparison 1: TRIFLUOPERAZINE versus LOW‐POTENCY ANTIPSYCHOTIC DRUGS, Outcome 8 Adverse effects: 2.b. Specific ‐ others. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/references#CD009396-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/image_n/nCD009396-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009396-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/urn:x-wiley:14651858:media:CD009396:CD009396-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/image_t/tCD009396-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analysis, Outcome 1 Response to treatment ‐ each low‐potency antipsychotic separately." data-id="CD009396-fig-0012" src="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/image_n/nCD009396-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analysis, Outcome 1 Response to treatment ‐ each low‐potency antipsychotic separately. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/references#CD009396-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/image_n/nCD009396-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009396-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/urn:x-wiley:14651858:media:CD009396:CD009396-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/image_t/tCD009396-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analysis, Outcome 2 Response to treatment ‐ treatment resistance." data-id="CD009396-fig-0013" src="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/image_n/nCD009396-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analysis, Outcome 2 Response to treatment ‐ treatment resistance.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/references#CD009396-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/image_n/nCD009396-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009396-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/urn:x-wiley:14651858:media:CD009396:CD009396-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/image_t/tCD009396-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sensitivity analysis, Outcome 1 Response to treatment ‐ fixed effects model." data-id="CD009396-fig-0014" src="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/image_n/nCD009396-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Sensitivity analysis, Outcome 1 Response to treatment ‐ fixed effects model. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/references#CD009396-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/media/CDSR/CD009396/image_n/nCD009396-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD009396-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Other reviews suggested by excluded studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Suggested title</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Excluded study tag</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Alternate use of different antipsychotics for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009396-bbs2-0034" title="WilsonIC , McKayJ , SandiferMG . A double‐blind trial to investigate the effects of thorazine (largactil, chlorpromazine), compazine (stemetil, prochlorperazine) and stelazine (trifluoperazine) in paranoid schizophrenia. Journal of Mental Science1961;107:90‐9. ">Wilson 1961</a> (trifluoperazine and chlorpromazine) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Combined multi‐drug therapy for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009396-bbs2-0009" title="CaseyJF , HollisterLE , KlettCJ , LaskyJJ , CaffeyEM . Combined drug therapy of chronic schizophrenics. Controlled evaluation of placebo, dextro‐amphetamine, imipramine, isocarboxazid and trifluoperazine added to maintenance doses of chlorpromazine. American Journal of Psychiatry1961;117:997‐1003. ">Casey 1961</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trifluoperazine and chlorpromazine combination for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009396-bbs2-0013" title="DeWolfeAS , BarrellRP , LondonL , SpanerFE . Prolixin enanthate and thorazine‐stelazine regimens in the treatment of schizophrenic patients. An experimental evaluation. Psychosomatics1971;12(3):186‐90. ">DeWolfe 1971</a>, <a href="./references#CD009396-bbs2-0026" title="SmithJA , ChristianD , RutherfordA , MansfieldE . A comparison of triflupromazine (vesprin), chlorpromazine and PLACEBO in 85 chronic patients. American Journal of Psychiatry1958;115:253‐4. ">Smith 1958</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trifluoperazine doses for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009396-bbs2-0011" title="CraneGE . High doses of trifluperazine and tardive dyskinesia. Archives of Neurology1970;22(2):176‐80. ">Crane 1970</a>, <a href="./references#CD009396-bbs2-0024" title="PrienRF , LevineJ , ColeJO . High dose trifluoperazine therapy in chronic schizophrenia. American Journal of Psychiatry1969;126(3):305‐13. ">Prien 1969</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trifluoperazine versus mid‐potency antipsychotics for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009396-bbs2-0016" title="GardosG , FinnertyRJ , ColeJO . Thiothixene and trifluoperazine in a step system. Psychosomatics1970;11(1):36‐40. ">Gardos 1970</a> (thiothixene), <a href="./references#CD009396-bbs2-0018" title="HamiltonM , HordernA , WaldropFN , LofftJ . A controlled trial on the value of prochlorperazine, trifluoperazine and intensive group treatment. British Journal of Psychiatry1963;109:510‐22. ">Hamilton 1963</a> (prochlorperazine) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trifluoperazine versus other high‐potency antipsychotics and anxiolytics for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009396-bbs2-0021" title="MarjerrisonG , HrychukW , VarsanyiEI . A comparison of two butyrophenones with trifluoperazine. Canadian Psychiatric Association Journal1966;11(1):26‐30. ">Marjerrison 1966</a> (triperidol, haloanisone), <a href="./references#CD009396-bbs2-0023" title="PrienRF , LevineJ , ColeJO . High dose therapy in chronic schizophrenia ‐ trifuoperazine. Proceedings of the 121st Annual Meeting of the American Psychiatric Association; 1968 May 13‐17; Boston, Massachusetts, USA. 1968. ">Prien 1968</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trifluoperazine versus other phenothiazine (unknown) antipsychotics for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009396-bbs2-0025" title="RudyL , RinaldiE , HimwichH , TuteurW , GlotzerJ . Trifluoperazine in the treatment of psychotic patients. American Journal of Psychiatry1958;115:364‐5. ">Rudy 1958</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trifluoperazine versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009396-bbs2-0019" title="HershonHI , KennedyPF , McGuireRJ . Persistence of extra‐pyramidal disorders and psychiatric relapse after withdrawal of long‐term phenothiazine therapy. British Journal of Psychiatry1972;120(554):41‐50. ">Hershon 1972</a>, <a href="./references#CD009396-bbs2-0022" title="PlatzAR , KlettCJ , CaffeyEM . Selective drug action related to chronic schizophrenic subtype (A comparative study of carphenazine, chlorpromazine, and trifluoperazine). Diseases of the Nervous System1967;28(9):601‐5. ">Platz 1967</a>, <a href="./references#CD009396-bbs2-0024" title="PrienRF , LevineJ , ColeJO . High dose trifluoperazine therapy in chronic schizophrenia. American Journal of Psychiatry1969;126(3):305‐13. ">Prien 1969</a>, <a href="./references#CD009396-bbs2-0033" title='WestonFK , LoftusAP . A terminal double‐blind trial of tri‐fluoperazine ("stelazine") in chronic schizophrenia. Medical Journal of Australia1961;48(1):776‐80. '>Weston 1961</a> </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Other reviews suggested by excluded studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/full#CD009396-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009396-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Design of a future study</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Methods</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: randomised ‐ clearly described generation of sequence and concealment of allocation.<br/> Blinding: double ‐ described and tested.<br/> Duration: long term. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>People with schizophrenia or schizophrenia‐like disorder.<br/> N = 500.<br/> Age: any.<br/> Sex: both.<br/> History: any. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Trifluoperazine (oral).</p> <p>2. Any low‐potency antipsychotic (oral).</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Response (primary outcome)</p> <p>Rehospitalisation</p> <p>Mental state (BPRS)</p> <p>Global state (CGI)</p> <p>Leaving the study early (including specific causes)</p> <p>Death (natural and unnatural causes)</p> <p>Side‐effects</p> <p>Quality of life</p> <p>Satisfaction with care</p> <p>Employment</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p>BPRS ‐ Brief Psychiatric Rating Scale<br/> CGI ‐ Clinical Global Impression </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Design of a future study</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/full#CD009396-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009396-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Trifluoperazine versus low‐potency antipsychotic drugs for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Trifluoperazine versus low‐potency antipsychotic drugs for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with schizophrenia<br/> <b>Settings:</b> Inpatients and outpatients<br/> <b>Intervention:</b> Trifluoperazine versus low‐potency antipsychotic drugs </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Trifluoperazine versus low‐potency antipsychotic drugs</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Response to treatment ‐ medium term</b> <br/> Follow‐up: 4‐6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.96</b> <br/> (0.59 to 1.56) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>120<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>364 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>349 per 1000</b> <br/> (215 to 567) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>350 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>336 per 1000</b> <br/> (206 to 546) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Leaving the study early: 1. Acceptability of treatment ‐ leaving early due to any reason</b> <br/> Follow‐up: 1‐4 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.25</b> <br/> (0.72 to 2.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>239<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>160 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> <br/> (115 to 348) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>182 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>228 per 1000</b> <br/> (131 to 395) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse events: 1. General ‐ at least one adverse effect</b> <br/> Follow‐up: mean 4 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.6</b> <br/> (0.94 to 2.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>60<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>375 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>600 per 1000</b> <br/> (352 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>375 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>600 per 1000</b> <br/> (352 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse events: 2.a. Specific ‐ movement disorders ‐ at least one movement disorder</b> <br/> Follow‐up: 6‐26 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 2.08</b> <br/> (0.78 to 5.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>123<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>89 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>186 per 1000</b> <br/> (70 to 496) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>104 per 1000</b> <br/> (39 to 278) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0<sup>4</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sedation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0<sup>5</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0<sup>5</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect. <br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk of bias: rated 'serious' ‐ most information is from studies at unclear risk of bias, missing or unclear results for incomplete outcome data and selective reporting<br/> <sup>2</sup> Imprecision: rated 'serious' ‐ the total number of events is less than 300 and the estimate of effect includes appreciable benefit/harm.<br/> <sup>3</sup> Imprecision: rated 'serious' ‐ the total number of events is less than 300 and the CI is quite wide<br/> <sup>4</sup> There were no data for this very important outcome<br/> <sup>5</sup> There were no data for this outcome </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Trifluoperazine versus low‐potency antipsychotic drugs for schizophrenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/full#CD009396-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009396-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Series of similar reviews</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reference</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol versus low‐potency antipsychotic drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009396-bbs2-0076" title="TardyM , LeuchtS , PotapovA , KisslingW , EngelR , HuhnM , et al. Haloperidol versus low‐potency first‐generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews2011, Issue 8. [DOI: 10.1002/14651858.CD009268] ">Tardy 2011b</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flupenthixol versus low‐potency antipsychotic drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009396-bbs2-0074" title="TardyM , LeuchtS , PotapovA , EngelR , DoldM , KisslingW . Flupenthixol versus low‐potency first generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews2011, Issue 8. [DOI: 10.1002/14651858.CD009227] ">Tardy 2011</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fluphenazine versus low‐potency antipsychotic drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009396-bbs2-0075" title="TardyM , LeuchtS , PotapovA , EngelR , HuhnM , KisslingW . Fluphenazine versus low‐potency first generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews2011, Issue 8. [DOI: 10.1002/14651858.CD009230] ">Tardy 2011a</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Perphenazine versus low‐potency antipsychotic drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009396-bbs2-0077" title="TardyM , LeuchtS , PotapovA , EngelR , HuhnM , KisslingW . Perphenazine versus low‐potency first generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews2011, Issue 10. [DOI: 10.1002/14651858.CD009369] ">Tardy 2011c</a> </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Series of similar reviews</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/full#CD009396-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009396-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Comparison 1: TRIFLUOPERAZINE versus LOW‐POTENCY ANTIPSYCHOTIC DRUGS</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Response to treatment ‐ medium term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.59, 1.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Leaving the study early: 1. Acceptability of treatment ‐ leaving early due to any reason <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>239</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.72, 2.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.70, 2.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.13, 30.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Leaving the study early: 2. Due to adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>239</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.44 [0.48, 4.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.44 [0.48, 4.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Leaving the study early: 3. Due to inefficacy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>239</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [0.22, 8.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.21, 18.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.03, 15.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Relapse <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.60 [0.64, 4.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.07, 14.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.64 [0.52, 5.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.92 [0.29, 12.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Adverse events: 1. General ‐ at least one adverse effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.6 [0.94, 2.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Adverse events: 2.a. Specific ‐ movement disorders <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 at least one movement disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.08 [0.78, 5.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 akathisia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.06 [0.65, 56.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 akinesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.02 [0.13, 31.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 dyskinesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.04 [0.37, 43.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5 incoordination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.0 [1.60, 30.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6 rigor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.5 [1.58, 12.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Adverse effects: 2.b. Specific ‐ others <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 anticholinergic ‐ blurred vision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.76 [0.49, 194.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 anticholinergic ‐ drooling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.0 [0.39, 41.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 cardiovascular ‐ dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.03, 16.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 cardiovascular ‐ syncope</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.03, 15.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5 central nervous system ‐ drowsiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.31, 2.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.6 central nervous system ‐ insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.7 central nervous system ‐ lethargy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.86 [0.25, 137.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.8 central nervous system ‐ muscle weakness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.0 [0.39, 41.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.9 central nervous system ‐ seizure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.10 central nervous system ‐ slurred speech</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.13, 30.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.11 central nervous system ‐ tenseness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.03, 15.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.12 dermatological ‐ skin disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.28, 3.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.13 gastrointestinal ‐ decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.14 metabolic ‐ polydipsia and polyuria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Comparison 1: TRIFLUOPERAZINE versus LOW‐POTENCY ANTIPSYCHOTIC DRUGS</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/references#CD009396-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009396-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Subgroup analysis</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Response to treatment ‐ each low‐potency antipsychotic separately <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 versus chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.54, 2.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 versus thioridazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.43, 1.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Response to treatment ‐ treatment resistance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.59, 1.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Not treatment resistant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.8 [0.40, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Treatment resistant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.58, 2.26]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Subgroup analysis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/references#CD009396-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009396-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Sensitivity analysis</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Response to treatment ‐ fixed effects model <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.8 [0.40, 1.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Sensitivity analysis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009396.pub2/references#CD009396-tbl-0007">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD009396.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD009396-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD009396-note-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD009396-note-0002">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD009396-note-0001">Hrvatski</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009396\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009396\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009396\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009396\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009396\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009396\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009396\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009396\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009396\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009396\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009396\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009396\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009396\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009396\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009396\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009396\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009396\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009396\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=fw9sVDQH&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009396.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009396.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD009396.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD009396.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009396.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725751891"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009396.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725751895"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009396.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e82e33f16936d',t:'MTc0MDcyNTc1My4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 